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Cardiovascular disease is the leading cause of death in the United States and globally. 
Atherosclerosis is an important basis for coronary heart disease and stroke, the two major types of 
cardiovascular disorders. Fabry disease promotes accelerated atherogenesis and thrombogenesis 
by loss of activity of the lysosomal hydrolase, α-Galactosidase A (GLA), resulting in the 
accumulation of globotriaosylceramide (Gb3) in vascular endothelial cells. Although endothelial 
dysfunction, characterized by decreased nitric oxide bioavailability, is believed to be the basis for 
the vasculopathy in Fabry disease, the pathophysiological mechanisms underlying GLA deficiency 
remain elusive. Using Fabry disease as a model to study accelerated vascular disease, the overall 
purpose of my dissertation was to further characterize endothelial dysfunction and inflammation 
using murine and in vitro endothelial cell models of Fabry disease, and to examine the effects of 
12 weeks of voluntary exercise on endothelial function in the setting of eNOS dysregulation. The 
major findings of my dissertation studies include that: 1) GLA deficiency in mice resulted in early, 
profound endothelial dysfunction in the mesenteric artery, which was associated with eNOS 
uncoupling and changes in eNOS activating and inhibitory phosphorylation sites; 2) the in vitro 
disruption of GLA in endothelial cells with siRNA or CRISPR/Cas9 directly promoted a decrease 
in eNOS activity and robustly elevated the secretion of von Willebrand factor (VWF), which plays 
an important role in thrombi formation; 3) pharmacological approaches that improve exogenous 
or endogenous NO availability or reduce reactive oxygen species (ROS) completely normalized 
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the elevated VWF secretion in the setting of GLA deficiency; and 4) 12 weeks of voluntary wheel 
exercise did not significantly improve endothelium-mediated vasodilation or the oxidative stress 
profile despite increased p-Akt (Ser473), AMPK (Thr172), and eNOS (Ser1177) signaling 
cascades in the aorta of 12-14 month old GLA deficient mice. Overall, the findings from these 
dissertation projects suggest that in Fabry disease: 1) decreased NO availability due to eNOS 
uncoupling and elevated ROS may exacerbate endothelial dysfunction and inflammation; 2) VWF  
release from the endothelium appears to be mediated by the profound endothelial dysfunction 
present in GLA deficiency; 3) strategies that increase NO bioavailability and/or decrease ROS, 
such as sepiapterin, tempol, and ebselen lead to an attenuation in VWF secretion; and 4) exercise 
mediated activation of Akt/AMPK/eNOS signaling cascades without significant improvement in 
aortic endothelial function in 12-14 month old GLA deficient mice. In summary, this dissertation 
compliments the prior hypothesis that GLA deficiency-mediated eNOS dysregulation is an 
important basis for endothelial inflammation and questions whether current treatment strategies 







Statement of the Problem 
 
Heart disease is the leading cause of death in the United States, and cardiovascular disease accounts 
for nearly 30% of all deaths annually (7). However, many heart disease and stroke deaths could be 
delayed through treatment of risk factors and improvements in lifestyle behaviors.  
Fabry disease is an X-linked inborn error of glycosphingolipid metabolism caused by a defect in 
the gene encoding the lysosomal enzyme α-Galactosidase A (GLA), resulting in a toxic 
accumulation of globotriaosylceramide (Gb3) in various organ systems (1, 6). This accumulation 
of Gb3, especially in the vascular endothelium, is coupled with impaired endothelial function in 
patients with Fabry disease, ultimately leading to premature death from cardiac disease and strokes 
(4). The current standard of care for Fabry patients is enzyme replacement therapy (ERT) using 
recombinant human GLA. Although this treatment is effective in reducing Gb3 accumulation in 
multiple cell types, the average cost per patient of the ERT is tremendous (over $215,000 / year), 
which makes therapy difficult to obtain for these patients (4). In addition, emerging evidence 
suggests that ERT does not prevent the natural course of cardiac disease, cerebrovascular disease, 
or nephropathy in all patients once the damage from this disease is far advanced (8, 10). In contrast, 
Gaucher disease, the most common of the lysosomal storage disorders, is effectively treated with 
replacement of its defective enzyme, beta-glucocerebrosidase (2). This indicates that the vascular 
complications in Fabry disease do not entirely depend on Gb3 accumulation. It is, therefore, 
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important to investigate the cellular mechanism(s) underlying the Fabry vasculopathy and to 
identify better treatment strategies. A recent study that screened more than 1,400 patients with 
common forms of heart disease, such as coronary artery disease and cardiomyopathy, has reported 
that elevated urinary Gb3 is positively associated with and predicts near-term mortality in heart 
disease patients who do not have Fabry disease (9). This suggests that heart disease in common 
clinical settings is associated with glycolipid metabolism abnormalities. Therefore, although Fabry 
disease is a very rare genetic condition, a greater appreciation of the role of this glycosphingolipid 
storage disease on endothelial dysfunction may have broad implications for our understanding of 
cardiovascular disease pathophysiology. 
 
The outline of my dissertation is as follows: 
A. Endothelial dysfunction and inflammation in the setting of GLA deficiency. 
• PROJECT 1: Determination of endothelium-dependent dilation and signaling 
alterations of the endothelial nitric oxide synthase in the mesenteric artery in younger 
and older mice deficient in GLA compared to age-matched wild type mice.  
• PROJECT 2: Examination of endothelial inflammation and possible mechanisms of 
alterations in von Willebrand factor secretion in cellular models of Fabry disease. 
B. Effects of exercise on endothelial dysfunction and inflammation in the setting of GLA 
deficiency. 
• PROJECT 3: Investigation of the effects of 12 weeks of voluntary wheel running on 
endothelial nitric oxide synthase uncoupling and endothelial inflammation in the mouse 




The overall objective of my dissertation projects is to advance understanding of endothelial 
dysfunction and inflammation in murine and cellular models of Fabry disease and to examine 
possible roles of voluntary wheel exercise on endothelial nitric oxide synthase dysregulation in the 
setting of GLA deficiency. History has revealed that the study of rare lipid disorders can lead to 
the discovery of specific mechanisms and/or therapeutic interventions for cardiovascular disease. 
For example, previous studies on rare familial hypercholesterolemia characterized by LDL 
receptor deficiency led to the discovery of the regulation of cholesterol metabolism (5) and the 
current class of medications (i.e. statins) that have proven useful for reducing cardiovascular 
disease mortality in high risk patients (3). Therefore, the findings of these dissertation projects 
have important implications for identifying new strategies for preventive and therapeutic 
interventions for vasculopathy in Fabry disease, in addition to fundamentally advancing the fields 
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Review of Literature 
 
Despite the success in reducing the mortality from acute cardiovascular events, cardiovascular 
disease (CVD) and its complications still produce immense health and economic burdens as the 
main cause of death in the United States and globally (115).  Compelling scientific evidence 
suggests that the endothelium plays a pivotal role in the regulation of vascular tone, growth, 
thrombogenicity, atherogenicity, and inflammation (90). Moreover, it is evident that the presence 
of endothelial dysfunction is associated with cardiovascular events (66). Therefore, it is important 
to understand how the endothelium regulates vascular homeostasis in physiological and 
pathophysiological conditions. Strategies designed to prevent endothelial dysfunction may 
therefore reduce cardiovascular complications. 
 
Endothelial nitric oxide synthase in normal physiologic condition 
Human vasculature is composed of three layers: the endothelium (intima), smooth muscle cells 
(media), and surrounding elastic and connective tissues (adventitia). The innermost monolayer of 
the endothelial cells sense hemodynamic forces and respond to physiologic and pathologic stimuli 
(51, 52, 66, 85). Also, the endothelium, as the primary interface between the blood and body tissues, 
governs several important aspects of vascular responses through the generation of nitric oxide 
(NO), a gas produced by nitric oxide synthase (NOS) enzymes (43, 50-52, 133). There are three 
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major isoforms of NOS: neuronal NOS (nNOS), or type 1 NOS; inducible NOS (iNOS), or type 2 
NOS; and endothelial NOS (eNOS), or type 3 NOS (66). eNOS is the predominant NOS isoform 
in the vasculature and is responsible for most of the NO produced in this tissue (42). As a multi-
domain enzyme, eNOS consists of an N-terminal oxygenase domain and a reductase domain 
(Figure 2 - 1). The oxygenase domain contains binding sites for heme, L-arginine, and 
tetrahydrobiopterin (BH4), and the reductase domain contains binding sites for flavin 
mononucleotide (FMN), flavin adenine dinucleotide (FAD), nicotinamide adenine dinucleotide 
phosphate (NADPH) and calmodulin (CaM) (22, 142). eNOS oxidizes its substrate L-arginine and 
produces L-citrulline and NO, the most prominent vasodilatory agent (3, 33). The functional eNOS 
requires dimerization of the enzyme, the presence of the substrate L-arginine, and the essential 
cofactor BH4 (43). eNOS is classified as a constitutive enzyme that produces NO in a Ca2+ / CaM 
dependent manner (17).  The CaM-binding domain of eNOS has been reported to directly bind 
phospholipids, and functional eNOS was found to be primarily localized in caveolae of the plasma 
membrane (61, 98, 144, 163). Caveolae are small invaginations of the plasma membrane, which 
sequester diverse receptors and function to organize various signaling transduction pathways 
including eNOS (93). The major structural proteins of caveolae are cholesterol, glycosphingolipids, 
sphingomyelin, and caveolin-1 (cav-1) (143). Cav-1 is abundant in endothelial cells and inhibits 
eNOS activity in the basal state by impeding the signaling of caveolae-targeted receptors that 
transduce eNOS-stimulatory signals as well as by antagonizing calmodulin binding to eNOS (47, 
76). Heat shock protein 90 (Hsp90) is a chaperone that is involved in protein trafficking and folding 
and agonist-dependent eNOS activation (108). Hsp90 is known to reduce the inhibitory effects of 
cav-1 on eNOS (41, 55). Upon an increase in cytoplasmic calcium, CaM is thought to aid the 
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recruitment of Hsp90 to eNOS and facilitate the effects of Hsp90 on the dissociation of eNOS 
from caveolin-1. 
eNOS is known to be activated by various physiological stimuli, including mechanical shear stress 
(23, 52, 60, 111, 169), insulin (129), acetylcholine (68), and other receptor-dependent agonists (7) 
(Figure 2 - 2). eNOS is regulated by post-translational phosphorylation at several serine (S) and 
threonine (T) residues including T495, S615, S633, and S1177 (13, 33). Among those potential 
phosphorylation sites, phosphorylation of eNOS at S1177 residue in the reductase domain and 
phosphorylation at T495 within the CaM-binding domain have been most studied. T495 is 
constitutively phosphorylated and associated with a decrease in enzyme activity (40, 59, 109). 
S1177 phosphorylation results in more active eNOS and NO production, even at resting levels of 
intracellular calcium (103). eNOS-derived NO serves several important functions. First, it 
regulates vascular tone and regional blood flow (68). Second, it modulates the expression of 
surface cell adhesion molecules that governs interactions with circulating cells including 
leukocytes, monocytes, and platelets, therefore affecting propensity or resistance to atherosclerotic 
plaque formation and thrombosis (21, 44, 82, 89). Finally, NO also inhibits the proliferation and 
injury responses of vascular smooth muscle cells, which could contribute to neointima formation 
during the development of atherosclerosis (114, 134, 155). Based on the combination of those 







Figure 2 - 1. Catalysis of endothelial nitric oxide synthase 
This figure depicts eNOS that functions as homodimers. Each monomer consists of an N-
terminal oxygenase domain and a reductase domain. The oxygenase domain contains binding 
sites for heme, L-arginine, and tetrahydrobiopterin (BH4). The reductase domain contains 
binding sites for flavin mononucleotide (FMN), flavin adenine dinucleotide (FAD), 
nicotinamide adenine dinucleotide phosphate (NADPH) and calmodulin (CaM). eNOS oxidizes 
its substrate L-arginine and produces L-citrulline and NO, the most prominent vasodilatory 
agent. The functional eNOS requires dimerization of the enzyme, the presence of the substrate 
L-arginine, and the essential cofactor BH4. Abbreviations: L-Arg: L-arginine; BH4: 
tetrahydrobiopterin; CaM: calmodulin; FMN: flavin mononucleotide; FAD: flavin adenine 






Figure 2 - 2. Biological roles of endothelial nitric oxide 
This figure depicts biological roles of endothelial NO. eNOS is activated by physiological and 
metabolic stimuli including shear stress and receptor-dependent agonists. Phosphorylation of 
eNOS at S1177 increases its activity. NO generated from eNOS inhibits platelets aggregation, 
modulates leukocyte-endothelial cell interactions, inhibits smooth muscle cell proliferation, and 
regulates vascular tone. eNOS catalytic activity depends on the intracellular localization to 
caveolae and the protein-protein interactions with caveolins and hsp-90. NO diffuses to vascular 
smooth muscle cells and induces smooth muscle cell relaxation through cGMP-PKG pathway, 
which increases luminal diameter and blood flow. Abbreviations: P: phosphorylation; S1177: 
serine 1177; HSP-90: heat shock protein-90; PKG: serine-threonine-specific protein kinase G. 




Protein regulation by S-nitrosylation and vesicle trafficking 
As mentioned above, NO has a variety of effects on vascular cells including smooth muscle 
relaxation, inhibition of smooth muscle cell migration and proliferation, platelet adherence and 
aggregation, and vascular inflammation. Among these effects, NO may regulate vascular 
inflammation and thrombosis, in part, by controlling endothelial vesicle trafficking (94). Vesicle 
trafficking involves several discrete stages: cargo loading, budding, translocation, priming, 
membrane fusion, and recycling (73, 75, 107, 156). Weibel-Palade bodies (WPBs) are released 
from endothelial cells following this cycle of vesicle trafficking upon endothelial inflammation 
and injury (94). WPBs are cigar-shaped granules that contain both pro-thrombotic and pro-
inflammatory factors, mainly von Willebrand Factor (VWF) and P-selectin (164, 167). The release 
of VWF into the blood stream promotes platelet adhesion and aggregation (135). WPB exocytosis 
also leads to the translocation of P-selectin to the endothelial cell plasma membrane, which 
regulates leukocyte rolling and extravasation (102, 104). After WPB exocytosis, the empty granule 
recycles back to the Golgi (94). Distinct sets of proteins regulate the cycle of WPB trafficking, 
including Rab family members, N-ethylmaleimide sensitive factor (NSF), soluble NSF attachment 
receptor proteins (SNAREs), and the Sec/Munc family (73, 75, 107, 156). Rab proteins are small 
GTPases that regulate vesicle tethering to target membranes (179). The SNAREs are a group of 
transmembrane proteins that specify fusion partners and assemble into stable ternary complexes 
(74). For example, one v-SNARE (VAMP-3) localized on the endothelial granule can interact with 
two t-SNAREs (syntaxin-4 and SNAP-23) localized to the plasma membrane, making a stable 
SNARE complex (99). The assembly of the SNARE complex is accelerated by Sec/Munc proteins 
(145). In contrast, NSF disassembles the three part SNARE complex by converting the chemical 
energy of ATP hydrolysis into mechanical energy (101).  
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NO has been reported to react with free thiol groups on cysteine residues of target proteins in a 
process called S-nitrosylation (153). Protein S-nitrosylation is a posttranslational modification 
where the binding of NO to cysteine residues can induce covalent changes in protein function 
(127). Out of the many proteins that regulate vesicle trafficking, NSF is a critical part of the 
exocytic machinery and a target of S-nitrosylation (10, 97, 99). Several experiments supported this 
notion by showing exogenous NO-mediated nitrosylation of 3 of the 9 cysteine residues in 
recombinant NSF as well as endogenous NO-mediated nitrosylation of NSF in wild type mice 
through blockage of NO production with NOS inhibitor or in eNOS null mice (99). Therefore, NO 
may inhibit WBP exocytosis by NSF nitrosylation at a cysteine 264 residue because nitrosylation 
or a mutation of this site blocked NSF separation of the SNARE complex (99, 100).  
It is also reported that S-nitrosylation is reversible (99). Thioredoxin is a reductase that maintains 
redox balance within cells, and is involved in many processes (16). Thioredoxin 1 (TRX1) is 
expressed in the cytosol, and reduces oxidized cysteine residues on target proteins. In endothelial 
cells TRX1 has a pro-inflammatory role because it is recruited to nitrosylated NSF, removes NO 
moieties, and restores exocytosis of WPBs (72). Therefore, the relative availability of NO and the 
activity of TRX1 regulate NSF function, subsequently influencing WPB exocytosis. 
 
Endothelial nitric oxide synthase in pathological condition 
Endothelial dysfunction is a broadly defined term used to describe a failure of the endothelium to 
serve its normal physiologic and protective effects (29, 171). A common feature associated with 
many cardiovascular risk factors (including hypertension, diabetes, insulin resistance, obesity and 
hyperlipidemia) is endothelial dysfunction (66). Because the endothelium normally protects 
against the processes involved in atherosclerosis, smooth muscle cell proliferation, inflammation 
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and thrombosis using NO, endothelial dysfunction is central to the pathogenesis of atherosclerotic 
lesion development. A mechanism of endothelial dysfunction is insufficient endothelial NO 
availability (67). A decline in NO bioavailability could be caused by many different factors. These 
include reduced eNOS gene expression, a lack of its substrate L-arginine, inhibition of eNOS by 
asymmetric dimethylarginine, uncoupling of eNOS and BH4 deficiency, metabolic intoxication by 
free fatty acids and inflammatory cytokines IL-6 and TNFα, alterations of intracellular signaling 
pathways of eNOS, and rapid scavenging of NO by superoxide anion (12, 26, 27, 66, 80, 123, 172). 
Two important causes of endothelial dysfunction seem to be accelerated NO degradation by 
reactive oxygen species (ROS) and eNOS uncoupling. There are many potential enzymatic sources 
of ROS in mammalian cells. These include the mitochondrial respiration, arachidonic acid 
pathway enzymes lipoxygenase and cyclooxygenase, cytochrome p450s, xanthine oxidase, 
NADPH oxidases, eNOS, peroxidases, and other hemoproteins (18). Although many of these 
sources could potentially produce ROS that inactivate NO, xanthine oxidase, NADPH oxidase, 
and eNOS have been studied rather extensively in the cardiovascular system.  
Xanthine oxidase is a form of xanthine oxidoreductase, which reduces molecular oxygen to 
produce O2- and H2O2 (18). Studies suggested that O2- derived from xanthine oxidase can decrease 
NO bioavailability because blood pressure in spontaneously hypertensive rats was dramatically 
lowered by a recombinant form of superoxide dismutase or the xanthine oxidase inhibitor 
oxypurinol (118). Also, oxypurinol reduced O2- production and improved impaired acetylcholine-
mediated vascular relaxation in the aorta of hyperlipidemic rabbits (120). These suggest that 
xanthine oxidase contributes to endothelial dysfunction by altering NO bioavailability. 
NADPH oxidase (NOX) is a membrane-bound enzyme complex and catalyzes one electron 
transfer of oxygen from NADPH to generate O2- and H2O2 (91). The oxidases are multi-subunit 
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enzymes that are expressed in vascular smooth muscle cells (NOX1 and NOX4) and in endothelial 
cells (NOX2 and NOX4) (2, 37, 53, 84). Cardiovascular risk factors, such as hypertension, diabetes, 
and hypercholesterolemia, increase the expression and/or activity of NOX in the vascular wall, 
enhancing the production of ROS (63, 77, 91, 128, 166). Both basal and NADPH-stimulated O2- 
formation was significantly increased in the rat aorta with heart failure (8). Subsequent treatment 
with superoxide dismutase (SOD) improved the impaired endothelium-dependent vasorelaxation. 
This evidence suggests that activation of this source of O2- can lead to a decrease in NO 
bioavailability and endothelial dysfunction.  
eNOS has received substantial attention as another source of vascular ROS production (18, 43, 66). 
There has been evidence that eNOS becomes uncoupled in various pathophysiological conditions 
(63, 83, 110, 112, 160). This phenomenon is named  “eNOS uncoupling” because O2- generation 
mainly occurs when eNOS is not coupled with its cofactor or substrate (95). BH4 is an essential 
cofactor necessary for optimal eNOS activity (4). For full enzymatic activity, eNOS requires 
proper dimerization (66). When BH4 levels are inadequate, eNOS becomes unstable and produces 
less NO and more O2- (Figure 2 - 3). Under conditions of eNOS uncoupling and/or high oxidant 
stress, O2- reacts with NO to form peroxynitrite anion (ONOO-) in a very rapid reaction (123). 
Importantly, ONOO- has multiple effects, including selective nitration of tyrosine residues in 
proteins (56), increased expression of inducible NOS (25), oxidation of the zinc-thiolate complex 
in eNOS (180), and oxidation of BH4 to BH2 (88). Interestingly, BH2 also can promote eNOS 
uncoupling because it can competitively replace eNOS-bound BH4 (28). 
Although multiple mechanisms can lead to O2- generation and eNOS uncoupling simultaneously, 
the common feature is a reduction in the amount of NO bioavailability, which protects the 
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vasculature, under normal healthy physiological condition, from the molecular events that lead to 






Figure 2 - 3. Coupled eNOS and uncoupled eNOS 
This figure depicts the role of eNOS uncoupling in the pathogenesis of endothelial dysfunction. 
eNOS is inactive when it is bound to cav-1 localized to the plasma membrane. When it becomes 
active, eNOS disassociates from cav-1 and binds with calmodulin (CaM) and heat shock protein 
90 (Hsp90) with phosphorylation at Serine1177. When availability of L-arginine or BH4 levels 
are insufficient, eNOS becomes unstable, resulting in less NO production and more superoxide 
generation. Moreover, peroxynitrite, a potent oxidant product from NO and superoxide, further 
oxidizes BH4, leading to eNOS uncoupling as a vicious cycle with subsequent endothelial 
dysfunction. Abbreviations: cav-1: caveolin-1; BH4: tetrahydrobiopterin; CaM: calmodulin; 





Lipid accumulation in the endothelium and cardiovascular disease 
Accumulation of lipids within the arterial wall is the principal cause and progression of 
atherosclerotic lesion (133). The deposition of the fatty streak precedes the influx of 
macrophages and T lymphocytes (154). This inflammatory response stimulates migration and 
proliferation of smooth-muscle cells and becomes intermixed with the area of inflammation to 
form an intermediate lesion. Lipid-rich advanced atherosclerotic plaques are pro-inflammatory 
and more prone to rupture and thrombosis than lipid-poor plaques (117). Therefore, the 
composition of lipid fractions within the atherosclerotic plaque may play a crucial role in the 
progression of atherosclerosis and in the complications of atherosclerotic vascular disease 
including myocardial infarction and stroke. 
 
α-Galactosidase A deficiency (Fabry disease) 
Fabry disease is caused by deficiency or absence of activity of the lysosomal enzyme α-
galactosidase A (GLA) (15, 81). It was first recognized in two affected brothers as a disease 
characterized by abnormal vacuoles in blood vessels throughout their bodies, suggesting a storage 
disorder (125). Reduced GLA activity may result from multiple different GLA gene mutations, 
which lead to reduced or complete deficiency of enzyme activity, or dysfunctional enzyme with 
low activity (24, 139). Since GLA hydrolyses the substrates possessing terminal α-galactosidic 
residues, the glycolipid conversion of globotriaosylceramide (Gb3) to lactosylceramide is impeded 
in Fabry disease (113). As a result, the progressive lysosomal accumulation of neutral 
glycosphingolipids with terminal α-galactosyl moieties is observed. The predominant site of 
glycosphingolipid accumulation is the endothelium and smooth muscle cells of the vasculature, 
although accumulation can occur in various other organ systems such as skeletal muscle cells, 
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histiocytes, reticulocytes, corneal epithelial cells, glomerulus and tubules of the kidney, ganglions 
of autonomous nervous system, epithelial cells, and others (36, 38, 157).  
Early signs and symptoms of Fabry disease include episodic acute pain (Fabry crisis) characterized 
by agonizing burning pain in the extremities and gastrointestinal involvement with abdominal pain, 
diarrhea, nausea, and vomiting (19, 64, 147). Other clinical manifestations of Fabry disease include 
renal failure, painful neuropathies, stroke, cardiac disease, and skin lesions (49). However, 
premature life-threatening complications result from cardiovascular diseases including myocardial 
infarction, stroke, hypertrophic cardiomyopathy, and renal failure with frequent detection in more 
than 60 % of affected males and heterozygous females (92, 105). Before renal dialysis and renal 
transplants became widely available, the average age at death among untreated males was reported 
as approximately 40 years (175). Although the increased availability of renal replacement therapy 
extended the lifespan of Fabry patients, it is still several decades shorter than the United States 
general population (96, 140, 165). 
 
Prevalence rate and treatments for Fabry disease 
The prevalence rate of Fabry disease was conventionally estimated to be 1 case in 40,000-117,000 
male births (106). However, more recent studies of newborn screenings now suggest the incidence 
of Fabry disease to be between 1 in 3,100 and 1 in 1,250 with later-onset phenotypes including 
hemodialysis, hypertrophic cardiomyopathy and stroke, raising the clinical importance of the 
condition in the future (69, 152). Although inheritance of GLA is X-linked, many heterozygotes 
will develop early symptoms and, later on, vital organ involvement (96, 170, 174).  
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Several potential therapies for Fabry disease, including bone marrow transplantation, substrate 
deprivation, recombinant GLA enzyme replacement, and gene therapy, have shown promise in 
pre-clinical trials in mice (1, 71, 78, 122). Whereas enzyme replacement therapy (ERT) with 
recombinant GLA is the only approved therapy for Fabry disease, there is no clear evidence that 
ERT alters the natural course of cardiac and cerebrovascular diseases (35, 130, 161).  
 
Basic research models of Fabry disease 
Because it is a rare disease, animal and cellular models of Fabry disease have been invaluable 
models for exploring the vascular pathophysiology of human genetic disease as well as for the 
development of effective therapeutic strategies. The combined homologous recombination and 
embryonic stem cell technology has allowed generation of knock-out mice for Fabry disease (121). 
This animal model has played an important role in studies of vascular pathogenesis. Although the 
GLA null mouse does not display a spontaneous vascular phenotype, recent studies reported 
several inducible models of vasculopathy. First, mice deficient in GLA showed a significant 
reduction in the time to occlusive thrombus formation with age compared to wild type C57BL6/J 
mice when exposed to photochemical reactive oxygen species (34). Accumulation of Gb3 on the 
carotid artery with age was associated with the enhanced thrombotic response to photochemical 
injury in GLA deficient mice. No changes in the vascular phenotype with bone marrow 
transplantation between GLA deficient and wild type mice suggested that the pro-thrombotic 
phenotype was not due to an abnormality of circulating blood elements, but most likely to changes 
localized to the vessel wall (34). Second, because glycosphingolipids have been shown to 
accumulate in atherosclerotic plaques of the human aorta (116), it is also possible that Gb3 
deposition in the vascular wall may promote atherogenesis. To address the potential role of GLA 
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deficiency in atherosclerosis, the GLA null mice were bred with apolipoprotein E deficient mice. 
At 45 weeks of age, Gb3 accumulation due to GLA deficiency was associated with a significant 
increase in total atherosclerotic burden (11). In a third model, acetylcholine mediated vascular 
relaxation was measured in the aortic rings from wild type and GLA-null mice pre-contracted with 
phenylephrine (124). The impaired vascular reactivity to acetylcholine in the GLA deficient rings 
was normalized with calcium ionophore-mediated NO production, suggesting a plasma 
membrane-based defect. Primary aortic endothelial cells from GLA deficient mice demonstrated 
that the increased plasma membrane Gb3 was the basis for the abnormality (148, 149). The Gb3 
accumulation was associated with decreased eNOS expression, activity, and levels of high 
molecular weight caveolin-1 oligomers (150). These results suggest that Gb3 alters the assembly 
of signaling molecules with caveolin-1, including eNOS. 
To study the molecular mechanisms, a cellular model of Fabry disease was also established. When 
the primary aortic endothelial cells from wild type and GLA null mice in various ages were 
compared, an age-dependent elevation in Gb3 was observed only in the GLA null cells (148). The 
glucosylceramide synthase inhibitor, ethylenedioxyphenyl-P4, significantly decreased Gb3 level 
by 96 hours of treatment. Recombinant GLA completely eliminated Gb3 accumulation by 48 hours 
of incubation. In addition, a single and low dose for a shorter period of incubation with a 
combination of ethylenedioxyphenyl-P4 and recombinant GLA had a synergistic effect. In a more 
recent study, GLA was transiently silenced using a RNA interference technique in an immortalized 
human umbilical cell line, EA.hy926 (151). An interesting finding of this study is that there was a 
decrease in eNOS activity consistent with the impaired formation of NO. In addition, a 50-fold 
increase in 3-nitrotyrosine was observed only in the GLA null cells, but not in the cells with β–
glucocerebrosidase knockdown, an enzyme responsible for the most common lysosomal storage 
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disease Gaucher disease. This significant elevation of 3-nitrotyrosine, but not of other tyrosine 
adducts, was also measured in GLA null mouse plasma and aorta as well as in the plasma of 
classical Fabry patients, suggesting that eNOS uncoupling with reactive nitrogen species formation 
was specific to Fabry disease (151). 
 
Dysregulation of endothelial nitric oxide synthase in Fabry disease 
Two primary hypotheses have been proposed to explain the pathogenesis of the vasculopathy of 
Fabry disease. One hypothesis suggests that circulating lyso-Gb3 deposition in the medial layer of 
the arterial vasculature is the initiating step of the vasculopathy. This promotes smooth muscle cell 
proliferation in the subendothelial layer and formation of neointimal fibrotic structures. A resultant 
hyperdynamic circulation in a less compliant vascular wall leads to upregulation of the local renin-
angiotensin system, and subsequent production of reactive oxygen species with a decrease in NO 
synthesis (132).  
An alternative hypothesis suggests that Gb3 accumulation in the endothelium alone is sufficient to 
account for the dysregulation of eNOS, which leads to low NO production and eNOS uncoupling 
with aberrant formation of reactive oxygen species (151) (Figure 2 - 4). The potential role for 
eNOS dysregulation with Gb3 accumulation in the endothelium is well supported by the cellular 
model of Fabry disease (151). In this study GLA knockdown induced a time dependent Gb3 
accumulation in human endothelial cells. This toxic deposition was associated with decreased NO 
activity. Uncoupling of eNOS was also confirmed by a highly robust elevation in 3-nitrotyrosine, 
the ONOO- nitration product, in this cell line, GLA null mouse plasma and aorta, as well as in the 
plasma of classical Fabry patients. Also, Gb3 loading in skin microvascular endothelial cells 
resulted in an increase in reactive oxygen species and the transcription of intercellular adhesion 
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molecule-1, vascular cellular adhesion molecule-1, and E-selectin (146). In addition, Gb3 content 
was markedly increased in the total plasma membrane as well as the caveolar fraction of primary 
mouse aortic endothelial cells from GLA null mice (148, 149). These observations were consistent 
with decreased eNOS expression, hormone-stimulated eNOS activity, and high molecular weight 
caveolin-1 oligomers, indicating increased plasma membrane Gb3 is the basis for the endothelial 
dysfunction (150). This hypothesis was further supported by an observation that impaired Ach-
mediated vascular relaxation of GLA null mouse aorta was eliminated with calcium ionophore-
stimulated dilation (124). In addition, the GLA knockout mice display increased thrombogenesis 
and atherogenesis when exposed to reactive oxygen species and bred on an apolipoprotein E1-
deficient background, respectively (11, 34). Together, although many different factors could play 
a role in the vascular abnormality present in Fabry disease, common factors are an alteration of 






Figure 2 - 4. Gb3 deposition in the endothelium leads to endothelial dysfunction 
This figure depicts the role of Gb3 accumulation in the vascular endothelial cells. Deficient or 
absent activity of GLA results in Gb3 accumulation in the endothelium. This leads to decreased 
NO bioavailability and eNOS uncoupling with the formation of reactive oxidants. These 
promotes thrombosis, atherosclerosis, and impaired vasodilation in the aorta. Also, NO from 
eNOS binds to O2- to generate ONOO-, a highly reactive nitrogen species, resulting in protein 
nitration (3-NT). ONOO- can oxidize BH4 to BH2. BH2 can efficiently replace eNOS-bound 
BH4, resulting in further eNOS uncoupling.  Abbreviations: GLA: α-galactosidase A; Gb3: 
globotriaosylceramide; eNOS: endothelial nitric oxide synthase; NO: nitric oxide; O2-: 





Mechanisms by which exercise improves endothelial dysfunction 
Many studies have demonstrated exercise to be one of the most effective non-pharmacological 
interventions for improving endothelial dysfunction. During the last two decades, the beneficial 
effects of exercise on attenuated endothelial function have been extensively studied in various 
aspects including aging, heart disease, hypercholesterolemia, hypertension, and type II diabetes 
mellitus.  
Impaired endothelium-dependent dilation (EDD) with aging is thought to be mediated by reduced 
NO bioavailability associated with increased oxidative stress (18, 32, 159). Three months of 
habitual aerobic exercise improved impaired EDD in middle-aged and older adults (31, 141, 158, 
159). This was thought to be mediated in part by an enhanced NO bioavailability because a greater 
degree of forearm vasoconstriction with intra-brachial artery infusion of an eNOS inhibitor was 
observed after exercise intervention (158). Also, acute administration of supraphysiological 
concentrations of vitamin C improved EDD only in sedentary men, but not in endurance exercise-
trained men, indicating that the improvement in EDD may be secondary to reduced oxidative stress. 
These observations suggest that this influence is mediated by an increase in NO bioavailability 
and reduced oxidative stress.  
A number of studies have reported that reduced EDD in hypercholesterolemia is reversed or 
prevented by exercise training in mice and rabbits (119, 126, 178). In a genetic mouse model of 
hypercholesterolemia, aortic EDD was decreased compared to wild type mice, but four weeks of 
treadmill training restored normal EDD (119). Six weeks of treadmill training reduced carotid 
artery neointima formation with an increase in eNOS expression in apo E null mice compared to 
sedentary apo E null mice (126). Studies using aorta, carotid, and mesenteric arteries in 
spontaneously hypertensive rats have consistently shown that impaired Ach mediated EDD and 
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NO production were improved by exercise training (6 – 22 weeks) (5, 20, 54). Additionally, 
reduced aortic EDD in OLETF type 2 diabetic rats was restored by 9 weeks of voluntary wheel 
exercise (138). In this study, urinary NO2, a stable degradation product of NO in biological 
solutions, was significantly increased by exercise compared to non-diabetic OLETF and sedentary 
control OLETF rats, suggesting exercise-mediated improvement in NO production. Together, one 
of the most important molecular consequences of exercise is the absolute increase in NO 
bioavailability.  
Exercise may exert its beneficial effect, in part, by shear stress. Shear stress induced by blood flow 
is one of the most important exercise-mediated physiological regulators of vascular tone (85). 
Numerous investigations have documented that exercise or increased shear stress up-regulates 
eNOS activity in cell culture, animal, and human studies (14, 57, 176). The beneficial effects of 
exercise on endothelial function are the result of changes in endothelial cell phenotype that involve 
increased eNOS expression and activity (57, 86, 87). Other markers of endothelial cell phenotype 
changes induced by exercise/shear stress include increased expression and activity of SOD and 
decreased oxidative stress (45, 136, 137). Because NO can be rapidly inactivated by reaction with 
O2- and lead to the production of the strong oxidant ONOO-, SOD may regulate NO-mediated 
signaling by inhibiting oxidative inactivation of NO (46, 123). Shear stress may exert its beneficial 
effects by not only increasing NO production, but also up-regulating SOD expression. Indeed, an 
NO donor (DETA-NO) increased the expression of vascular extracellular SOD in a time- and dose-
dependent manner in human aortic smooth muscle cells (45). This effect was prevented by a 
guanylate cyclase inhibitor and by a protein kinase G inhibitor, indicating NO may stimulate SOD 
expression and thereby prevent degradation of NO. Therefore, the beneficial effect of exercise on 
EDD observed in several studies may not only be due to an increase in eNOS expression (58, 62, 
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65), but also due to an increase in SOD expression, which decreases O2- reaction with NO. 
Importantly, unidirectional laminar shear stress significantly increased mRNA, protein content, 
and activity of cytosolic Cu/Zn SOD in human aortic endothelial cells, which would further 
enhance NO bioavailability in response to exercise/shear stress (70). 
 
Summary of review of literature 
The overall goal of my dissertation projects is to understand Gb3 accumulation on endothelial 
dysfunction and inflammation and to identify strategies for attenuating this progression in the 
setting of GLA deficiency. Although the vasculopathy is the basis for the life-threatening 
complications of Fabry disease, one of the early symptoms appearing in childhood is 
gastrointestinal involvement, which may be related to the deposition of Gb3 in the autonomic 
ganglia of the bowel and mesenteric blood vessels (39). However, the vascular phenotype in the 
mesenteric artery is unknown. Therefore, the objective of my first study is to characterize 
endothelial function of the mesenteric artery and to determine signaling alterations of eNOS in 
GLA deficient mice. Additionally, although ERT has been the standard care for Fabry disease, 
cerebral vascular events continue to occur in Fabry patients with advanced disease treated with 
long-term ERT (131, 168, 173). Endothelium-derived VWF plays a pivotal role in platelet 
adhesion and subsequent thrombus formation, supporting normal hemostasis and thrombosis (177). 
Previously, prothrombotic and proinflammatory profiles have been documented in Fabry disease 
(30, 48, 146, 162). However, less attention has been paid to the direct effect of GLA deficiency on 
the endothelium-derived coagulation factor, VWF. The second study of my dissertation projects, 
therefore, examines the effects of GLA disruption on VWF secretion and its association with eNOS 
dysregulation in in vitro models of Fabry disease. Finally, although exercise is known to improve 
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endothelial dysfunction in many conditions including diabetes, hypertension, and sedentary aging, 
the effects of exercise on endothelial dysfunction and inflammation in Fabry disease remain 
unclear. Thus, the third project uses a mouse model of Fabry disease to examine whether exercise 
improves endothelial dysfunction in the setting of eNOS uncoupling.  
The rationale for the proposed studies is that once it is known how GLA deficiency leads to 
vasculopathy, factors that affect endothelial dysfunction and inflammation can be manipulated 
either up or down pharmacologically and/or non-pharmacologically (exercise). Therefore, findings 
of the proposed research have important implications for the prevention and treatment of Fabry 
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Endothelial nitric oxide synthase uncoupling and microvascular dysfunction in the 
mesentery of mice deficient in a α-Galactosidase A 
 
Abstract 
A defect in the gene for the lysosomal enzyme α-galactosidase A (GLA) results in 
globotriaosylceramide (Gb3) accumulation in Fabry disease and leads to premature death from  
cardiac and cerebrovascular events. However, gastrointestinal symptoms are often first observed 
during childhood in these patients and are not well understood. In this study, we demonstrate an 
age-dependent microvasculopathy of the mesenteric artery (MA) in a murine model of Fabry 
disease (Gla-knockout mice) resulting from dysregulation of the vascular homeostatic enzyme 
endothelial nitric oxide synthase (eNOS). The progressive accumulation of Gb3 in the MA was 
confirmed by thin-layer chromatographic analysis. A total absence of endothelium-dependent 
dilation was observed in MAs from mice at 8 mo of age, while suppression of ACh-mediated 
vasodilation was evident from 2 mo of age. Endothelium-independent dilation with sodium 
nitroprusside was normal compared with age-matched wild-type mice. The microvascular defect 
in MAs from Fabry mice was endothelium-dependent and associated with suppression of the active 
homodimer of eNOS. Phosphorylation of eNOS at the major activation site (Ser1179) was 
significantly downregulated, while phosphorylation at the major inhibitory site (Thr495) was 
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remarkably enhanced in MAs from aged Fabry mice. These profound alterations in eNOS 
bioavailability at 8 mo of age were observed in parallel with high levels of 3-nitrotyrosine, 
suggesting increased reactive oxygen species along with eNOS uncoupling in this vascular bed. 
Overall, the mesenteric microvessels in the setting of Fabry disease were observed to have an early 
and profound endothelial dysfunction associated with elevated reactive nitrogen species and 
decreased nitric oxide bioavailability. 
 
Introduction 
Fabry disease is an X-linked glycosphingolipid disorder caused by deficient or absent activity in 
the lysosomal enzyme, α-galactosidase A (Gla) (3, 13). The loss of Gla leads to the progressive 
accumulation of neutral glycosphingolipids with terminal Gal-α1-4Gal linkages, including 
globotriaosylceramide (Gb3), galabiosylceramide, and globotriaosylsphingosine. A primary site 
of glycosphingolipid accumulation is the vascular endothelium, although accumulation occurs in 
various other organ systems throughout the body (6, 24). Premature life-threatening complications 
arise from involvement of the brain, heart, and kidneys and include cerebrovascular accidents, 
myocardial infarction, and progressive renal insufficiency (7). Affected hemizygous males and 
female carriers suffer from Fabry-related complications (15, 26). 
The vascular complications of Gla deficiency have been the primary focus of clinical and 
mechanistic studies of this rare disease. However, the earliest and most common symptoms of 
Fabry disease are gastrointestinal and include abdominal pain, constipation, diarrhea, and nausea 
(7, 21). Because these symptoms are common, the diagnosis of Fabry disease is often delayed (21).  
Both clinical and experimental studies have focused on the hypothesis that endothelial dysfunction 
may underlie both the macrovascular and microvascular complications associated with Fabry 
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disease. The Gla knockout mouse can be used to characterize and study inducible models of 
vasculopathy. Robust vascular phenotypes in these mice have been reported, including accelerated 
atherogenesis and thrombus formation following photochemical injury (2, 5). In isolated aortic 
rings, Gb3 accumulation in endothelium is linked to a defect in endothelial nitric oxide (NO) 
mediated vasodilation (18). These and other findings are consistent with a Gb3 dependent loss of 
NO bioavailability as a common mechanism linking atherogenesis, thrombosis, and impaired 
vasorelaxation.  
The purpose of this study was to determine whether the vascular phenotype in the Gla knockout 
mouse extends beyond the aorta and carotid vasculature. Specifically, an age-dependent 
mesenteric artery phenotype was characterized in Gla null mice. Gla deficient mice were observed 
to have age-dependent Gb3 accumulation in their mesenteric arteries in conjunction with a 





A breeding colony of Gla null mice was established from mice provided by Ashok Kulkarni at the 
NIH. The knockout mice (129/SvJXC57BL/6) were originally generated by replacement of α-
galactosidase A (Gla) gene with a neomycin resistance (neo) sequence within a portion of exon 3 
and intron 4 region (17). These mice were back-crossed a minimum of six generations to the 
C57BL6/J strain. The Gla null and wild-type (WT) C57BL/6 mice were maintained in University 
of Michigan animal facility under standard conditions. All animal experiments were performed 
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according to the protocol of the University of Michigan Committee on the Use and Care of 
Laboratory Animals. 
 
Vascular reactivity experiments 
Two to nine month old mice were euthanized with intraperitoneal pentobarbital (66.5 mg/kg). A 
segment of small intestine was removed and placed in a dissection Petri dish filled with cold 
physiological salt solution (mmol/L: NaCl 130, KCl 4.7, KHPO4 1.18, MgSO4 1.17, CaCl2 1.6, 
NaHCO3 14.9, dextrose 5.5, CaNa2 EDTA 0.03). The second order mesenteric arteries (2-3 mm in 
length) were carefully dissected and connective tissue surrounding the arteries was removed. The 
individual vessel segment was mounted on glass cannulas in a pressure myograph system (110P, 
Danish Myo Technology A/S, Aarhus, Denmark). The vessel diameter was monitored and 
analyzed digitally in real time (DMT Vessel Acqusition Suite 6.2, Danish Myo Technology A/S, 
Aarhus, Denmark). In studies to determine acetylcholine (Ach)-mediated relaxation without 
endothelium, the endothelium was denuded during the mounting procedure by exposing 
endothelial cells to an air bubble for 30 seconds. Mounted mesenteric arteries were bathed with 
warmed (37˚C) and aerated (95% O2 and 5% CO2) physiological salt solution. Mesenteric arteries 
were pressurized at 20 mmHg, and the pressure was increased 10 mmHg every 5 minutes until 
reaching 60 mmHg. The vessels were then equilibrated for 60 minutes. Prior to Ach- and sodium 
nitroprusside (SNP)-mediated vascular reactivity studies, the vessels were subjected to osmotically 
balanced high potassium-containing physiological salt solution (mmol/L: NaCl 14.7, KCl 100, 
KHPO4 1.18, MgSO4 1.17, CaCl2 1.6, NaHCO3 14.9, dextrose 5.5, CaNa2 EDTA 0.03) and various 
concentrations of norepinephrine (NE, 10-9 to 10-4 mol/L) with washes in between each contraction. 
Pre-constriction of the vessel was performed with NE (10-5 mol/L). Subsequently, Ach (10-9 to 10-
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4 mol/L) or SNP (10-8 to 10-3 mol/L) was added cumulatively to the bath to examine endothelium-
dependent (Ach) or endothelium-independent (SNP) relaxation. All chemicals used in the vascular 
reactivity study were purchased from Sigma Chemical Company (St. Louis, MO). 
 
Reagents  
Globotriaosylceramide (Gb3), was purchased from Matreya (Pleasant Gap, PA). Three 
phosphatase/protease inhibitors; P2714, P0044 and P5726, were obtained from Sigma-Aldrich (St. 
Louis, MO). Mouse anti-human eNOS monoclonal and mouse anti-human 3-nitrotyrosine 
monoclonal antibodies were purchased from Abcam (Cambridge, MA). Rabbit anti-human 
phospho-eNOS Thr495 polyclonal antibody was acquired from Cell Signaling Technology 
(Danvers, MA). Rabbit anti-bovine phospho-eNOS Ser1179 polyclonal antibody was from Life 
Technologies (Grand Island, NY). The ECL-plus system was from PerkinElmer Life Sciences 
(Waltham, MA).  
 
Tissue Lipid Extraction and Gb3 Analysis 
Frozen mesenteric artery (MA) tissues, dissected from WT and Gla null mice at ages between 1 
and 12 months, were thawed in 0.8 ml/sample of ice-cold sucrose buffer (250 mM sucrose, pH 7.4, 
10 mM Hepes and 1 mM EDTA) and homogenized with a Tri-R homogenizer at 10% output. Total 
and neutral lipid extraction, separation by high performance thin layer chromatography, and 





For immunoblot analysis, frozen MA tissues were thawed in ice-cold lysate buffer formulated with 
25 mM Tris-HCl (pH 7.4), 137 mM NaCl, 2 mM EDTA, 2 mM Na3VO4, 20 mM NaF, 1% Triton 
X-100, 10% glycerol and 1X mixture of phosphatase/protease inhibitors composed of P2714, 
P0044, and P5726. Unfrozen samples were homogenized with a Tri-R homogenizer for 20 seconds 
at 5% output at 4°C, and then sonicated with a probe sonicator for 1 second 5 times at 50% output 
at 4°C. The cell debris was removed by centrifugation at 10,000 × g for 10 minutes at 4°C. 
Quantification of total protein in each MA sample was performed by using bicinchoninic acid 
assay with bovine serum albumin as a standard. To determine total eNOS expression in MA of 
wild type and Gla null mice, 40 µg of MA lysate protein, either denatured with 1% 2-
mercaptoethanol or non-denatured, were separated by SDS-PAGE using a 6-12% gradient. 
Monomeric and homodimeric eNOS in WT and Gla null mouse MA were detected with a mouse 
anti-human eNOS monoclonal antibody at a concentration of 0.5 µg/ml. MA samples for 
determination of protein-bound 3-nitrotyrosine levels were dissected from WT and Fabry mouse 
in antioxidant buffer containing 100 μM diethylene tetraamino pentaacetic acid, 50 μM butylated 
hydroxytoluene, 10 μL/mL protease inhibitor (Pierce, Rockford, IL). Expression of 3-nitrotyrosine 
in MA samples were evaluated using a mouse anti-human 3-nitrotyrosine antibody (0.4 µg/ml) 
diluted in blotting buffer (TBS) consisting of 20 mM Tris-HCl (pH, 7.6), 150 mM NaCl and 2.5% 
fat-free dry milk. Primary antibodies against human p-eNOS Thr495 (0.5 µg/ml) and bovine p-
eNOS Ser1179 (1.0 µg/ml) residues were selected to measure phosphorylation of eNOS in wild 
type and Gla null mouse MA. Both antibodies were diluted in 1% milk-TBS. Based on amino acid 
sequence homology, all of the eNOS specific antibodies cross-react with indicated proteins in 
mouse MA. The immunoreactive bands were stained with the ECL-plus system and quantified by 





GraphPad Prism software was used for statistical analysis. The data are presented as mean ± 
standard error of the mean. Results were analyzed using unpaired t-test for comparison of two 
groups. For multiple comparisons, data were analyzed using two-way ANOVA, followed by 
Bonferroni post-hoc analysis. Statistical significance was set at p<0.05. 
 
Results 
Age-dependent Gb3 accumulation in the mesenteric arteries of Gla null mice. 
MAs from 2 and 9 month old wild type mice on a C57BL/6 background had no detectable Gb3. 
However, in Gla-deficient mouse MA, Gb3 levels were readily detected at 2 months of age and 
were markedly elevated in the 9 month old MA (Figure 3 - 1A). The Gb3 levels from 9 month old 
Gla null mouse MAs were 5 fold higher than that observed in 2 month old knockout MA (Figure 
3 - 1B) and continued to increase through 12 months of age (Figure 3 - 1C). These data indicate 
that the Gb3 accumulation in the Gla null mouse MAs is progressive as a function of age.  
 
Acetylcholine (Ach) mediated relaxation in endothelium-intact mesenteric arteries 
The endothelium-dependent relaxation to Ach was examined in isolated MAs from wild type and 
Gla null mice that were pre-contracted with norepinephrine (NE) (10-5 mol/L). The MAs from 2 
month-old Gla knockout mice dilated significantly less (15.9 ± 5.8%, p<0.001) when compared to 
vessels from age matched wild type mice (53.4 ± 9.2%) in response to the highest dose of Ach (10-
4 mol/L) (Figure 3 - 2A). The MAs from 8 month-old wild type mice relaxed in a concentration-
51 
 
dependent manner following exposure to Ach. In the wild type MAs the relaxation to the highest 
concentration of Ach (59.2 ± 5.6%) was comparable to that observed in the 2 month old mice. By 
contrast, the vessels from age-matched Gla null mice were nearly devoid of Ach-mediated 
dilatation (1.5 ± 5.8%, p<0.001) (Figure 3 - 2B). 
 
Sodium nitroprusside (SNP) -mediated relaxation in endothelium intact mesenteric arteries. 
The difference in Ach dependent relaxation could be secondary to a functional defect in either the 
endothelium or smooth muscle cells. To determine whether the responsiveness of the smooth 
muscle layer to nitric oxide is different between the wild type and Gla null vessels, sodium 
nitroprusside (SNP), a nitric oxide donor, was added at increasing concentrations. SNP induced an 
endothelium-independent vasodilatation in both wild type and knockout MAs. In 2 month old 
arteries, the maximum relaxation to SNP in wild type mouse MA (78.2 ± 2.2%) was not 
statistically different from Gla null mouse MA (84.2 ± 5.4%) (Figure 3 - 3A). The maximum 
relaxation observed in 8 month old MA was also no different between wild type (80.5 ± 5.0%) and 
Gla null (69.6 ± 4.3%) mice. However, the observed SNP responsiveness in vessels from the 8 
month old mice revealed a greater sensitivity at lower concentrations of SNP (10-7 to 10-6 mol/L) 
in wild type compared to null background  (Figure 3 - 3B).  
 
Acetylcholine- and sodium nitroprusside- mediated dilation in endothelium-denuded mesenteric 
arteries. 
It was next determined whether the attenuation in Ach-mediated relaxation observed in the Gla 
null mice was endothelium-dependent. The endothelium of the MA vessels was removed before 
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determining the Ach and SNP dose responses. As expected, denuding the MA endothelium 
inhibited any measurable vasodilatation in response to Ach in vessels from either wild type or Gla 
null mice (Figure 3 - 4A). SNP induced a concentration-dependent vasodilatation in both groups, 
and the maximum relaxation did not differ between wild type (75.9 ± 3.2%) and null (74.4 ± 5.7%) 
mice (Figure 3 - 4B). 
 
Decreased eNOS homodimers and monomers in the mesenteric arteries from Gla null mice.  
The basis for the decrease in NO bioavailability was next evaluated. The dimerization of eNOS is 
required for catalytic activity and NO production (28). Two forms of eNOS, monomers and 
homodimers, can be measured by polyacrylamide gel electrophoresis under reducing or non-
reducing conditions. A decrease in both eNOS dimers and monomers was observed in the null 
MAs compared to the wild type MAs from 8 month old mice (Figure 3 - 5A). This difference was 
confirmed with repeated measurements (Figure 3 - 5B). The observed 53% decrease in homodimer 
expression from the knockout mouse MA compared to wild type MA (eNOS to actin ratios of 1.39 
± 0.08 versus 0.66 ± 0.12 in wild type versus Gla knockout) was statistically significant. 
 
Serine1179 and threonine495 phosphorylation in the mesenteric arteries 
eNOS phosphorylation at Ser-1179 in MA was evaluated with an anti-bovine Ser-1179 antibody 
reacting crossly with mouse eNOS phospho-Ser-1179. Phosphorylation of eNOS-Ser-1179 was 
not observed in wild type or null MA extracts from 2 month old mice. However, phospho-Ser-
1179 was readily observed in 8 month old wild type and Gla knockout mouse MA (Figure 3 - 6A). 
A modest decrement in phospho-Ser-1179 was observed in the Gla null compared to the wild type 
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MAs (-21 ± 0.67%, p=0.0343) consistent with the down-regulation of eNOS activity (Figure 3 - 
6B). In contrast to this modest difference, the phosphorylation of eNOS at Thr-495 was markedly 
enhanced in aged Gla null MA (Figure 3 - 7A). A 16 fold increase in eNOS phosho-Thr-495 was 
observed in 8 month old Gla null MA compared to wild type MA. The marked increase in Thr-
495 phosphorylation is consistent with a suppression of eNOS activity (Figure 3 - 7B).  
 
Increased reactive nitrogen species in the mesenteric artery from Gla null mice 
Protein modification by nitration of tyrosine to 3-nitrotyrosine has been correlated with elevated 
oxidative stress and is specifically formed in the setting of eNOS uncoupling. The levels of protein-
bound 3-nitrotyrosine in both wild type and Gla null mouse MAs were measured using a specific 
antibody for protein-bound 3-nitrotyrosine. 3-Nitrotyrosine levels increased in both mouse lines 
as a function of age (Figure 3 - 8A). However, protein-bound 3-nitrotyrosine content was 
significantly higher (~4 fold) in Gla null MAs compared to wild type MAs at each age studied 
(Figure 3 - 8B). These findings suggest that the Gla null phenotype not only results in lower NO 




Consistent with previous findings in other vascular beds (5, 23), we observed an age-dependent 
accumulation of Gb3 in the mesenteric arteries of Gla null but not wild type mice. We also 
measured a significant reduction in the vasodilatory capacity of MA in Gla deficient mice. These 
data suggest that the endothelial dysfunction associated with Gb3 accumulation is widespread 
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within the vasculature and includes the gastrointestinal microvessels. Similar to the previous 
findings in aortic rings (18), an age- and endothelial cell-dependent dysfunction in the MA of Gla 
null mice was observed as manifest by a loss of acetylcholine stimulated vasodilation. The ability 
of sodium nitroprusside to restore the vasodilation was consistent with a primary defect in nitric 
oxide bioavailability. However, despite the profound nature of this defect, no spontaneous GI 
phenotype was observed in Gla null mice of any age. Surprisingly, the age of onset of the MA 
abnormality was earlier, and the magnitude of the endothelial dysfunction appeared greater 
compared to previously studied macrovessels that included the aorta and carotid arteries. 
eNOS dysfunction may result from either a decrease in nitric oxide bioavailability or uncoupling 
resulting in the formation of reactive nitrogen species. The active and functional form of eNOS is 
a dimer (20). We therefore measured the dimerization and expression of eNOS in the MA in Gla 
deficient and WT mice. In the older mice, both total eNOS expression and eNOS dimerization 
were decreased significantly, suggesting that uncoupling of eNOS in the mesenteric artery may, in 
part, contribute to the endothelial dysfunction. However, the measurement of eNOS monomers 
was also lower in Gla deficient mice and no difference in the eNOS monomer to homodimer ratio 
was evident between WT and Gla deficient mice at 2 or 8 months of age. In previous studies 
examining the effect of age on endothelial function in C57BL/6J mice, a significant increase in the 
eNOS monomer to dimer ratio in 24 months versus 3 months old mesenteric arteries was observed 
with no significant difference in total eNOS protein levels (27).  Therefore, the observed reduction 
in eNOS protein and monomers in Gla deficient mice does not appear to represent a simple 
acceleration of normal age-related changes.  Rather, the observed changes likely represent a 




Nitric oxide production can lead to the formation of peroxynitrite (ONOO-) in the setting of 
increased superoxide generation (9). Peroxynitrite is both an oxidant and nitrative agent that has 
been shown to induce cellular dysfunction and apoptosis (20). Possibly, the increased levels of this 
oxidant during sustained periods of oxidative stress or resulting from eNOS uncoupling caused a 
decrease in the expression of functional eNOS. To explore the possibility that some of the observed 
abnormalities were peroxynitrite mediated, the levels of 3-nitrotyrosine, an NO-dependent 
nitrosative stress marker in the MA was measured. 3-Nitrotyrosine was significantly elevated in 
the mesenteric artery from Gla knockout mice at 2 months of age, and the levels of 3-nitrotyrosine 
were further elevated in the older Gla null mice, consistent with the early onset and a progressive 
increase in eNOS uncoupling in the Fabry mesenteric arteries.  
To further characterize the altered eNOS regulation in Gla-deficient mice, post-transcriptional 
modifications to the eNOS protein were also evaluated.  The phosphorylation of eNOS at the Ser-
1179 and Thr-495 residues was studied. In general, phosphorylated Ser-1179 activates eNOS, and 
phosphorylated Thr-495 inhibits eNOS catalytic activity (1, 25), and at least four protein kinases, 
Akt, PKA, PKC, and AMPK, are known to target eNOS (16). Phosphorylation or 
dephosphorylation of Ser-1179 and Thr-495 potentially could be regulated reciprocally or 
independently by those kinases. PKC signaling is reported to result in the simultaneous 
phosphorylation and dephosphorylation of eNOS Ser-1179 and Thr-495 respectively (16). In 
addition, the phosphorylation state of Thr-495 is inversely associated with eNOS activation and 
NO production (8, 11, 16). Previous studies examining the function of mutant Thr-495 and Ser-
1179 cells have suggested that the ratio of phosphorylated to dephosphorylated Thr-495 may act 
as an intrinsic switch for determining whether eNOS generates nitric oxide or superoxide anion 
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(14). Therefore, we measured phosphorylation of eNOS at Thr-495 in the mesenteric artery to 
evaluate whether this site may be specifically altered in Gla null mice.  
Compared to age-matched WT mice, eNOS phosphorylation of Thr-495 was highly increased in 
Gla deficient mice in the older group, suggesting that phosphorylated Thr-495 may promote eNOS 
dysregulation in older Gla null mice. Although we did not observe elevated phosphorylation of 
Thr-495 at 2 months of age, we did observe evidence of elevated 3-nitrotyrosine at this younger 
age. These data are consistent with the interpretation that the modest early onset phenotype of 
endothelial dysfunction is linked to nitric oxide uncoupling through a mechanism that is 
independent of Thr-495 phosphorylation.  It is possible, therefore, that the more profound 
endothelial dysfunction present at 8 months is the result of the additional activation of the 
inhibitory eNOS Thr-495 site. 
In addition to alterations in nitric oxide, EDHF is also an Ach-mediated and endothelium produced 
factor, and we cannot rule out the possibility of an EDHF defect in the setting of Gla deficiency. 
A recent study reported that Gb3 incubation of mouse aortae partially inhibited Ach-mediated 
dilatation (19). In this paper, a significant decrease in KCa2+ channel current, mRNA and protein 
expression was observed in both mouse aortic endothelial cells from Gla knockout mice and WT 
mouse aortic endothelial cells treated with Gb3.  This study provided evidence that Gb3 
accumulation may contribute to vasculopathy through direct effects on intermediate-conductance 
KCa2+ channel activity (19).   
A growing body of evidence also suggests that the contribution of EDHF is at least as important 
as NO in terms of endothelium-dependent vascular relaxation in the microvasculature (4, 22). One 
could propose that a decrease in EDHF through KCa2+ channel blockade may contribute to the 
earlier onset and profound endothelial dysfunction observed in the MA in the present study. In 
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addition, pharmacologic blockade of the small and intermediate KCa2+ channels has been 
demonstrated to increase superoxide formation and enhance phospho-eNOS at Thr-495 without 
changes in the total eNOS protein levels (10). Thus, Gb3 accumulation may lead to an endothelial 
plasma membrane defect, which results in impaired or altered signaling of multiple endothelium-
dependent relaxing factors including NO and EDHF. Further studies designed to identify the 
underlying molecular mechanisms responsible for the microvascular phenotype in this mouse 
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Figure 3 - 1. Age-dependent accumulation of Gb3 in the mesenteric arteries of WT and 
Gla knockout mice 
Neutral glycosphingolipids were extracted and purified from MAs of 2 and 9 month old WT and 
Gla null mice. The neutral lipids, normalized to 50 nmol of total lipid phosphate, were spotted 
on high performance thin layer chromatography plates, and the bands were visualized by 
charring with 8 % cupric acetate in 8 % phosphoric acid solution. A. Representative separation 
of MA extracts from three separate mice per group. B. The combined densitometric analyses of 
the Gb3 levels from all mice. The data are pooled from three individual experiments with three 
mice per group (n=9 per group). C. Deposition of Gb3 in Fabry mouse MAs progressively 
accumulated from 1 to 12 months of age. Following lipid extraction, each sample containing 40 
nmol of total phospholipid phosphate was spotted onto a high performance thin layer 
chromatography plate. Each data point represents age (months) and average of triplicate samples 
(n=3). Abbreviations include: Gb3, globotriaosylceramide; SM, sphingomyelin; and Std, 









Figure 3 - 2. Acetylcholine (Ach)-mediated endothelium-dependent vasodilatation in the 
mesenteric arteries from WT and Gla knockout mice 
All vessels (n=4 per group) were pre-contracted with 10-5 M of NE. A. Percent relaxation in 
endothelium-intact mesenteric artery from 2 month old mice. B. Percent relaxation in 
endothelium-intact mesenteric artery from 8 month old mice. The data are expressed as the 
percentage of changes in lumen diameter relative to baseline. ** = p<0.01, and *** = p<0.001 









Figure 3 - 3. Sodium nitroprusside (SNP)-mediated, endothelium-independent 
vasodilatation in the mesenteric arteries from WT and Gla knockout mice 
All vessels (n=4 per group) were pre-contracted with 10-5 M of NE. A. Percent relaxation to 
SNP in endothelium-intact mesenteric arteries from 2 month old mice. B. Percent relaxation to 
SNP in endothelium-intact mesenteric arteries from 8 month old mice.  The data are expressed 
as the percent change in lumen diameter relative to baseline. * = p<0.05, and *** = p<0.001 











Figure 3 - 4. Acetylcholine (Ach)- and sodium nitroprusside (SNP)-mediated vasodilatation 
in endothelium-denuded mesenteric arteries from WT and Gla knockout mice 
All vessels (n=4 per group) were pre-contracted with 10-5 M of NE. A. Relaxation response as 
a function of Ach concentration in endothelium-denuded mesenteric arteries from 8 month old 
mice. B. Relaxation response as a function of SNP concentration in endothelium-denuded 
mesenteric arteries from 8 month old mice.  The data are expressed as the percentage change in 
lumen diameter relative to baseline. ** = p<0.01 compared to WT by two-way ANOVA 










Figure 3 - 5. eNOS levels in the mesenteric arteries of 8 month old WT and Gla null mice 
Mouse MA lysates equivalent to 50 µg of total lysate protein were analyzed by Western blot 
using a mouse anti-human eNOS antibody as an immuno-probe. A. A representative 
immunoblot for comparison of eNOS expression in the MAs of wild type (WT) and Gla 
knockout (KO) mice at 8 months of age (upper panel). The eNOS homodimer was only detected 
under non-reducing condition (lanes 1 and 2). Monomeric eNOS was probed under denaturing 
conditions using 1% 2-mercaptoethanol (lanes 3 and 4). β-actin was also probed an internal 
loading control (lower panel). B. Quantification of the MA monomeric and dimeric eNOS from 
8 month old WT and Gla null mice (n = 3 per group). The densitometric values represent the 









Figure 3 - 6. eNOS Ser-1179 phosphorylation in mesenteric arteries of 8 month old mice 
Total MA lysates equal to 80 µg of total lysate protein were subjected to a gradient SDS-PAGE 
(6-12%) separation and immunoblotting. The phosphorylation of eNOS Ser-1179 in WT and 
Gla null mouse MA was determined with a rabbit anti-bovine eNOS-S1179 antibody under non-
reducing conditions. A. Western blots from two sets of MAs dissected from WT and Gla null 
mice at the indicated ages (upper panel). β-actin was served as a loading control (lower panel). 
B. The combined densitometric data from four groups with 3 mice per group. The data were 









Figure 3 - 7. eNOS Thr-495 phosphorylation in the mesenteric arteries of WT and Gla 
knockout mice 
A total of 60 μg lysate protein from each sample was used for immunoblotting of eNOS Thr-495 
phosphorylation was measured under non-reducing conditions. A. A representative Western blot 
of phospho- Thr-495 (upper panel). β-actin was immunoblotted as an internal loading control 
(lower panel). B. Quantification of the immuno-signals of eNOS Thr-495 was performed by 
using ImageJ software. In the plotted graphic, each point represents the average value of three 









Figure 3 - 8. Expression of protein-bound 3-nitrotyrosine in the mesenteric arteries of WT 
and Gla null mice 
A. Fifty µg of Triton X-100 soluble MA lysate protein was immunoblotted using a protein-
bound nitrotyrosine specific monoclonal antibody. Reducing conditions with 1% 2-
mercaptoethanol were employed. B. Densitometric comparison of WT and Gla null protein-
bound 3-nitrotyrosine levels in the MAs in 2 and 8 month old mice. In the plotted graphic, each 
point represents the average value of three independent experiments. The data represent the 
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GLA deficiency promotes endothelial nitric oxide synthase dysregulation and robust VWF 
secretion from endothelial cells 
 
Abstract 
Fabry disease is caused by loss of activity of the lysosomal enzyme α-galactosidase A (GLA), 
leading to the accumulation of globo-series glycosphingolipids in vascular endothelial cells. 
However, the mechanism of the vasculopathy remains unclear. In this study the relationship 
between GLA deficiency and endothelial cell von Willebrand factor (VWF) secretion was 
explored. Plasma VWF was significantly higher at two months and further elevated with age in 
Gla-null compared to wild-type mice. The disruption of GLA by siRNA and CRISPR/Cas9 
resulted in a three and five fold increase in VWF secretion, respectively, in EA.hy926 human 
endothelial cells. Decreased endothelial nitric oxide synthase (eNOS) activity was associated with 
the elevated VWF levels in both in vitro models of Fabry disease. Pharmacological approaches 
that increase NO bioavailability or decreasing reactive oxygen species completely normalized the 
elevated VWF secretion in GLA deficient cells. However, the abnormality was not readily reversed 
by recombinant human GLA or by the inhibition of glycosphingolipid synthesis with eliglustat. 
This study suggests that GLA deficiency may promote robust VWF secretion through eNOS 





Fabry disease is a rare and often devastating lysosomal disorder caused by mutations in the α-
galactosidase A (GLA) gene resulting in a partial or complete absence of GLA activity (9). Fabry 
disease is X-linked, but heterozygous females may also develop clinically significant 
cardiovascular disease (28, 58). The deficiency in GLA causes a progressive deposition of one of 
its substrates, globotriaosylceramide (Gb3), primarily in vascular endothelial and smooth muscle 
cells (14, 44). Increased plasma levels of deacylated Gb3 (lyso-Gb3) are also present (1). The 
manifestations of Fabry disease occurring in childhood tend to be less severe and include 
angiokeratomas, neuropathic pain, hypohidrosis, and gastrointestinal symptoms (43). However, 
adult Fabry patients may develop life-threatening complications including stroke and renal failure 
(18).  
Thrombotic events have been reported in Fabry patients (50, 52). In addition, accelerated clot 
formation is observed in studies of experimentally induced models of thrombosis in Gla knockout 
mice (13, 45). Although enzyme replacement therapy (ERT) has been shown to reduce stored Gb3, 
evidence from clinical studies suggest that cerebral vascular events continue to occur in Fabry 
patients with advanced disease treated with long-term ERT (2, 40, 57, 59). Endothelial cells are 
among the most affected cell type in Fabry disease (12), in part secondary to decreased nitric oxide 
(NO) bioavailability and endothelial nitric oxide synthase (eNOS) uncoupling as noted in Study 1. 
Thus, factors regulating interactions of platelets and leukocytes at the endothelial level may be 
affected in the setting of GLA deficiency. von Willebrand factor (VWF), stored in Weibel-Palade 
bodies (WPB) of endothelial cells, is a large adhesive glycoprotein that plays a pivotal role in 
platelet adhesion and subsequent thrombus formation, supporting normal hemostasis and 
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thrombosis (61). High levels of VWF are predictive of an increased risk of thrombotic 
cardiovascular diseases, including stroke and coronary heart disease (33, 53, 55). Although a 
prothrombotic profile and increased production of reactive oxygen species (ROS) have been 
documented in Fabry disease (10, 17, 44, 54), less attention has been paid to the direct effect of 
GLA deficiency on the endothelium-derived coagulation factor, VWF.  
The purpose of this study was to examine the effects of GLA disruption on VWF secretion and its 
mechanistic link with NO bioavailability in endothelial cells. In addition, the in vitro endothelial 
cell model of GLA deficiency was exploited to evaluate the influence of treatment modalities to 




C57BL6/J mice were obtained from the Jackson Laboratory (Bar Harbor, ME). Gla null mice 
(129/SvJXC57BL/6) used in this study were bred from mice originally developed and provided by 
Drs. Ashok Kulkarni and Roscoe Brady (National Institutes of Health, Bethesda, MD) by 
replacement of α-galactosidase A (Gla) gene with a neomycin resistance sequence within a portion 
of the exon 3 and intron 4 region (37). These mice were back-crossed a minimum of six generations 
to the C57BL6/J strain. All mice were maintained in University of Michigan animal facility under 
standard specific pathogen-free conditions. All animal experiments were conducted according to 
the protocol of the Institutional Animal Care and Use Committee of the University of Michigan. 
 
Small Interfering RNA (siRNA) Silencing 
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The EA.hy926 human endothelial cell line (#CRL-2922) was purchased from ATCC (Manassas, 
VA). The cells were maintained in complete growth medium consisting of Dulbecco’s Modified 
Eagle Medium/F12, GlutaMAX (#ILT10565018, Life Technologies, Grand Island, NY), 10% fetal 
bovine serum, 100U/ml penicillin, and 100 µg/ml streptomycin. Anti-human siRNA 
oligonucleotides were purchased from AMS biotechnology (GLA: #SR301812; SCR: #SR30004, 
Cambridge, MA). Stock concentrations of the siRNAs were made at 20 µM in RNase-free 
reconstitution buffer consisting of 100mM potassium acetate and 30 mM HEPES (pH 7.5). 
Reconstituted siRNAs were heated at 94 ˚C for 2 min, and then cooled down to room temperature 
before storage at -20 ̊ C. Transfection was performed as described before with minor modifications 
(49). Briefly, approximately 9 x 105 cells were seeded in 100 mm petri dishes one day before the 
transfection. The transfection mixture was prepared immediately before addition. Forty microliter 
of Lipofectamine RNAiMAX (#13778, Life Technologies) was diluted into 1 mL of Opti-MEM-
I. The siRNA duplex, prepared in 1 mL of Opti-MEM-I, was added to diluted RNAiMAX reagent 
at 1:1 ratio and incubated at room temperature for 20 min to form the siRNA/transfection reagent 
complex. The culture medium was washed with 6 mL of Opti-MEM-I and replaced with 6 mL of 
Opti-MEM-I without serum and antibiotics. Two milliliter of the siRNA/transfection reagent 
complex with the siRNA duplex at a final concentration of 10 nM was then gently added into the 
cell culture dish. After 8 hours, the media was replaced with 10 mL of DMEM/F-12, GlutaMAX 
media containing 2% FBS without antibiotics. Two days after the first transfection, the cells were 
transfected again as described above. Transfected cells were harvested for the biotin switch assay 
and immunoblotting analyses 3 days after the second transfection. Cell culture supernatants were 
collected and spun down at 365 x g for 5 min to remove any cell debris. The samples were frozen 
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in liquid nitrogen and stored in -80 ˚C until analyzed. All the experiments were performed in cells 
at passage 3 or 4.   
 
CRISPR/Cas9 plasmid generation and delivery 
Single-stranded guide RNA was designed to target Exon 1 of GLA. Forward and reverse single-
stranded oligonucleotides were annealed to generate a double-stranded oligonucleotide. The 
oligonucleotide was cloned into the GeneArt CRISPR nuclease vector (Thermo Fisher Scientific, 
Waltham, MA), which expresses the orange florescence protein (OFP) reporter. The vector was 
transformed into One Shot TOP10 E. coli cells (Thermo Fisher Scientific, Waltham, MA). Bacteria 
were grown on LB agar plates with ampicillin and incubated at 37 °C overnight. Clones were 
selected and grown in LB broth overnight. Plasmids were purified and sequenced with the U6 
forward primer to verify the presence and proper orientation of double-stranded oligonucleotide. 
EA.hy926 cells were plated at 600,000 cells per well on 6 well dishes. The following day, the cells 
were transfected with 2 µg of CRISPR plasmid DNA using Lipofectamine 3000 (Thermo Fisher 
Scientific, Waltham, MA). Cells were grown in DMEM-F12 GlutaMAX supplemented with 10% 
FBS and FACS sorted 24 hours after transfection. OFP positive cells were collected and plated 
onto 150 mm dishes at low density in normal growth conditions. Cells were allowed to grow for 
several days, and then cloning cylinders were used to isolate individual colonies. Colonies were 
expanded and DNA was extracted using the DNeasy Blood and Tissue Kit (Qiagen, Germantown, 
MD). To detect mutations, the region around the CRISPR-targeted region was PCR amplified and 
the surveyor nuclease assay (Integrated DNA Technologies, Coralville, IA) was performed 
according to the manufacturer’s instructions. From 19 colonies isolated, 14 had a mutation in the 
CRISPR-targeted region. Western blot confirmed the absence of GLA expression in 4 of these 
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colonies. One of the GLA-negative cell lines was used for assays in this study. One wild type 
colony that was negative for a mutation in the surveyor assay was used as a wild type control in 
all assays.  
The primers used were: CRISPR guide RNA primers: forward 5’-GCT AGC TGG CGA ATC 
CCA TG (GTTTT)-3’, reverse 5’-CAT GGG ATT CGC CAG CTA GC (CGGTG)-3’; PCR 
primers: forward 5’-GCC CCT GAG GTT AAT CTT AAA AGC C-3’, reverse: 5’-AGC TCT 
CCC TCG GGC TCA ACT GTT C-3’. Parentheses denote the sequence complementary to the 3’ 
overhang sequence in the CRISPR nuclease vector. 
 
VWF antigen measurement  
Mouse plasma was withdrawn from wild type and GLA null mice at various ages via the retro-
orbital sinus using heparinized capillary tubes (#22362566, Fisher Scientific, Pittsburgh, PA). 
Blood was centrifuged at 2,000 x g for 10 min at room temperature to obtain platelet-poor plasma. 
The plasma was recovered, immediately frozen in liquid nitrogen, and stored at -80 °C for VWF 
analysis. CRISPR cells or EA.hy926 cells transfected with control (siSCR) or GLA (siGLA) were 
incubated in DMEM/F-12, GlutaMAX media containing 2% FBS for 3 days. Cell culture 
supernatants were collected and centrifuged at 365 x g for 5 min at room temperature to remove 
cell debris. These supernatants were concentrated using Amicon ultrafiltration units (#UFC903096, 
Sigma, St. Louis, MO) with 30 kDa molecular weight cutoff membranes at 3,000 x g for 15 
minutes. The samples were recovered, immediately frozen in liquid nitrogen, and stored at -80 °C 
for analysis of VWF. VWF antigen levels in the plasma and cell culture supernatants were 
determined using either a custom AlphaLISA (Perkin-Elmer) assay or enzyme-linked 
immunosorbent assay (ELISA) as described previously (11, 63). Briefly, polyclonal anti-human 
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VWF antibody (#A0082, DAKO, Glostrup, Denmark) was biotinylated using an NHS activated 
biotynylating reagent (Solulink, San Diego, CA). In addition, another set of antibody was 
conjugated to Alphalisa acceptor beads with sodium cyanoborohydride (Sigma, St Louis, MO). 
Plasma from WT and GLA null mice were thawed in 37°C water bath and diluted 1:160 in 
phosphate buffered saline pH 7.4. Twenty µL of each sample was plated in wells with 16 µL assay 
buffer containing biotinylated VWF antibody (0.5 nM) and VWF antibody-conjugated Alphalisa 
acceptor beads (10 µg/mL). After incubating for 60 minutes at room temperature, 24 µL of 
streptavidin coated donor beads (40 µg/mL) in assay buffer was added and incubated for an 
additional 30 minutes. The alpha signals were generated and detected on an EnSpire 2300 
Multilabel Plate Reader (Perkin Elmer). VWF levels in the plasma were calculated using a dilution 
series of pooled platelet-poor plasma from 10 C57BL/6J mice as a reference (100%). For ELISA, 
U-shaped bottom Maxisorp 96-well plates (#449824, Nunc) were coated with 50 µL/well of rabbit-
anti VWF (A0082, DAKO) in 50mM bicarbonate/carbonate buffer (1:500 at pH 9.8) at 4°C 
overnight. Next, the plates were washed 3 times with Tris-buffered saline containing 0.05% tween-
20 (TBST) and blocked with 300µL/well of 5% BSA in TBST at room temperature. After washing, 
50 µL of the analytes were added into the coated/blocked plates and incubated overnight at 4°C. 
After washing with TBST, the analytes were probed with horse radish peroxidase-conjugated 
VWF antibodies (1:4000 in 5% BSA in TBST) for 2 hours, followed by washes with TBST. Wells 
were developed (50 µL/well) with 3,3’,5,5’-Tetramethylbenzidine Stabilized Chromogen solution 
(#SB02, ThermoFisher, Waltham, MA) to detect HRP activity. The reaction was stopped by 
adding 2M sulfuric acid (50µL/well). The absorbance of each well was measured at 450nm. VWF 
levels in the cell culture supernatants were calculated using a dilution series of pooled normal 
plasma with known VWF antigen levels (FACT, George King Bioscience) as standards. Results, 
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which were normalized for the number of cells in each sample, were expressed as fold changes 
with respect to siSCR or CR-WT control condition. 
 
GLA Enzyme Activity Assay 
The enzyme activity was measured as described previously with minor modification (3). CRISPR 
cells were trypsinized, and cell pellet was obtained by centrifugation at 365 x g for 5 min. Pelleted 
cells were washed twice with cold PBS and homogenized in lysis buffer consisting 3 mg/mL of 
sodium taurocholate, 28 mM citric acid, and 44 mM Na2HPO4. The homogenates were sonicated 
for 3 min on ice (9 periods of 10 sec each with intervals of 10 sec in between), and centrifuged at 
20,000 x g for 30 min at 4°C to remove cell debris. Total protein level in each sample was 
quantified using bicinchoninic acid assay with bovine serum albumin as a standard. Three µg of 
protein in 20 µL of lysis buffer was added to 80 µL of assay buffer (5 mM p-Nitrophenyl α-D-
galactopyranoside (PNPαGal), 28 mM citric acid, 44 mM Na2HPO4, and 5 mg/mL BSA with 117 
mM N-acetyl-D-galactosamine) in a 96-well plate. N-acetyl-D-galactosamine was used as an 
inhibitor for α-N-acetylgalactosaminidase, another lysosomal enzyme that hydrolyses the 
PNPαGal substrate (32). GLA activity in the cell lysates were calculated using a dilution series of 
α-galactosidase (#G8507, Sigma) as a reference, which hydrolyzes 1.0 µmol of PNPαGal to p-
nitrophenol and D-galactose per minute. The assay plate was incubated at 37°C for 1 hr. Stop 
solution (100 µL of 200 mM Na2CO3) was then added and fluorescence was read on a plate reader 
(SpectraMax 250, Molecular devices, Sunnyvale, CA, USA) at 400 nm. 
 
eNOS activity measurements 
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Activity of endothelial nitric oxide synthase (eNOS) in EA.hy926 cell lysates was analyzed by 
using a NOS activity assay kit (#781001, Cayman Chemical, Ann Arbor, MI) according to the 
manufacturer’s instructions. This assay measures the biochemical conversion of L-arginine to L-
citrulline by NOS. Cells were harvested with 0.05% trypsin-EDTA and washed twice with PBS. 
Cell pellets were lysed in the provided homogenization buffer (final concentration 1 mM EDTA 
and 1 mM EGTA in 25 mM Tris-HCl (pH 7.4) buffer). After brief sonication, the samples were 
centrifuged at 21,130 x g for 5 minutes, and the supernatants transferred to new tubes. Cell lysates 
(5 µL) were incubated at room temperature for 3 hours with 1 µCi 3[H]arginine (PerkinElmer), 
100 nM calmodulin, and the provided reaction buffer (final concentration 1 mM NADPH, 600 µM 
CaCl2, 25 mM Tris-HCl (pH 7.4), 3 µM tetrahydrobiopterin, 1 µM flavin adenine dinucleotide, 
and 1 µM flavin adenine mononucleotide in 50 µL). The reaction was stopped by adding 400 µL 
of 5 mM EDTA in 50 mM HEPES (pH 5.5) buffer.  The provided kit resin was added to each 
sample to remove 3[H]arginine. Radioactivity due to 3[H]Citrulline radioactivity was measured as 
counts per minute (cpm) using a scintillation counter. NOS activity of each sample was calculated 
by subtracting background cpm from the cpm for each sample, and then normalizing to total 
protein in each 5 µL sample, determined by the bicinchoninic acid protein assay. 
 
Cell treatments 
One day before the second transfection, siRNA-transfected cells were incubated with vehicle (10 
mM HEPES) or DETA-NONOate (50µM, #82120 Cayman, Ann Arbor, MI). The following day, 
the cells were treated with either vehicle or the NO donor in 2% FBS DMEM/F12, GlutaMAX 
media for 3 days after the second siRNA transfection to investigate the effects of exogenous NO 
on VWF secretion. CRISPR cells were treated as described above with vehicle (10 mM HEPES) 
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or DETA-NONOate (100 µM). Because the half-life of DETA-NONOate is 20 hours at 37°C (24), 
DETA-NONOate was re-added every 20 hours during the treatment for 3 days. For studies on the 
effects of endogenous NO on VWF secretion, vehicle (0.3% DMSO) or sepiapterin (300 µM) were 
added to confluent CRISPR cells over 3 days. In separate sets of experiments, 1H-
[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, 5 µM) was added 1 hr before the addition of 
DETA-NONOate or sepiapterin to inhibit the activation of sGC by NO. For studies on human α-
galactosidase A (α-Gal A), cells were seeded, and incubated with either vehicle (25 mM Tris and 
150 mM NaCl, pH 7.5) or α-Gal A (10 ug/mL) from the following day for two days. After cell 
confluency was attained, the media was replaced with 2% serum containing media with one of the 
treatments or vehicle for additional three days. Either DMEM media as vehicle or eliglustat 




Levels of NSF S-nitrosylation were determined using a biotin switch assay as previously described 
(21).  Briefly, EA.hy926 cells were washed with cold Dulbecco’s Phosphate-Buffered Saline and 
lysed with HENS buffer (100 mM HEPES, 1 mM EDTA, 0.1 mM Neocuproine, 1% SDS, pH 8.0; 
Thermo Fisher, Waltham, MA). The lysates were sonicated using a probe sonicator (Branson 
sonifier 450) on ice for 30 seconds at output 2. Cell debris was removed by centrifugation at 10,000 
x g for 10 min. Positive control samples were incubated with 200 µM of S-nitrosoglutathion 
(GSNO) for 30 min in dark. Excess GSNO was removed by 7K MWCO Zeba spin desalting 
column (#89890, Thermo Fisher, Waltham, MA) according to the manufacturer’s instructions. 
Three hundred micrograms of proteins were subjected to the biotin switch assay. Free thiol 
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residues were first blocked with 20 mM of sulfhydryl-reactive compound S-methyl 
methanethiosulfonate (#64306, MMTS, Sigma-Aldrich, St. Louis, MO) for 20 min at 50 °C with 
vortexing every 5 min. Excess MMTS was removed by incubation in 5 mL of pre-chilled acetone 
at -20 °C for 20 min. The samples were pelleted by centrifugation at 3,000 x g for 10 min at 4 °C, 
and washed once with pre-chilled 70% acetone. The samples were resuspended in 240 µL of HENS 
buffer. S-nitrosylated cysteines were then selectively reduced by 1 mM of sodium ascorbate 
(#11140, Sigma-Aldrich, St. Louis, MO) and labeled with 30 µL of biotin (2.5 mg/mL in DMSO) 
N-[6-(biotinamido)hexyl]-3´-(2´-pyridyldithio) propionamide (#21341, biotin-HPDP, 
ThermoFisher, Waltham, MA) in the presence of 1 µM of CuCl (#AC208390250, Fisher Scientific) 
for two hours in the dark. Excess sodium ascorbate and unlabeled biotin were removed by acetone 
precipitation at -20 °C for 20 min. The samples were centrifuged at 5,000 x g for 10 min at 4°C, 
and washed once with pre-chilled 70% acetone. The samples were resuspended in 250 µL of 
HENS/10 buffer (HENS diluted 10-fold into H2O containing 1% SDS), and 750 µL of 
neutralization buffer (25 mM HEPES, 100 mM NaCl, 1 mM EDTA, 0.5% Triton X-100, pH 7.5) 
was added. Twenty five microliters from each sample was saved for analysis of total protein 
“input”. The residual was transferred to a tube containing 70 µL of pre-washed streptavidin 
immobilized on agarose beads and incubated overnight at 4°C with gentle rotation. The beads were 
centrifuged at 200 x g for 5 seconds, washed, and eluted in 30 µL HEN/10 containing 1% β-
mercaptoethanol for 20 min for immunoblotting analyses.  
 
Western blotting 
The cell lysates were prepared as described above. Quantification of total protein in each sample 
was performed by a bicinchoninic acid assay with bovine serum albumin as a standard. Thirty µg 
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of each sample lysate was separated by SDS-PAGE using a 4-12% gradient gel. Proteins were 
transferred onto nitrocellulose membranes, and blocked in 5% nonfat dry milk in TBST for at least 
1 hr. The membranes then were incubated overnight at 4°C with primary antibodies used at 1:1,000 
dilution; NSF (#2145, cell signaling, Danvers, MA), GLA (#LS-B8027, LS Bio, Seattle, WA), 
GAPDH (#MAB374, EMD Millipore, Billerica, MA), eNOS (#ab76198, Abcam, Cambridge, 
MA), and TRX-1 (#2429, Cell Signaling, Danvers, MA). After washing with TBST, the membrane 
was incubated with appropriate secondary antibody in 5% milk in TBST. The immunoreactive 
bands were detected with ECL western blotting substrate (#32106, Thermo Fisher, Waltham, MA), 
and quantified by densitometric scanning using ImageJ software. 
 
Quantitative RT-PCR 
WT and GLA null mice were perfused with 3 mL of cold PBS using a 25-gauge needle, inserted 
into the left ventricle, at a rate of 1 mL/min. Total RNA was extracted from lung and liver tissues 
with RNeasy Protect Mini Kit (#74124, Qiagen). Total cellular RNA was isolated using RNeasy 
Plus Mini Kit (#74134, Qiagen). Reverse transcription was performed using High Capacity cDNA 
Reverse Transcription Kit (#4368814, Applied Biosystems). Power SYBR Green PCR Master Mix 
(#4367659, Applied Biosystems) and cDNA were transferred to a 48-well plate, and real-time PCR 
was performed with a StepOne Real-Time PCR System instrument. Data were normalized to 
GAPDH or TATA binding protein, and the results were expressed relative to the WT mice or CR-
WT. The primers used were: mouse VWF primers: forward 5’-GGG TGA CCA AAG CAT CTC 
CA-3’, reverse 5’-CAT CGA TTC TGG CCG CAA AG-3’; mouse GAPDH primers: forward 5’-
GAC CAC AGT CCA TGC CAT CA-3’, reverse: 5’-ACT TGG CAG GTT TCT CCA GG-3’; 
human VWF primers: forward 5’-TTG ACG GGG AGG TGA ATG TG-3’, reverse 5’-ATG TCT 
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GCT TCA GGA CCA CG-3’; human GAPDH: forward 5’-TTG TTG CCA TCA ATG ACC CCT-
3’, reverse 5’-GAT CTC GCT CCT GGA AGA TGG-3’; human TBP: forward 5’-GCC GCC GGC 
TGT TTA ACT-3’, reverse 5’-ACG CCA AGA AAC AGT GAT GCT-3’. 
 
Statistical analysis 
GraphPad Prism software (Graphpad Software Inc., La Jolla, CA) was used for statistical analysis. 
The data were presented as mean ± SEM. Results were analyzed using the unpaired t-test for 




Endothelial activation in Gla null mice 
In previous studies Gla deficiency was demonstrated to accelerate vascular complications in mice 
including models of atherosclerosis on apoE null background and oxidant-induced arterial 
thrombosis (8, 13). Soluble vascular cell adhesion molecule-1 (sVCAM-1) and von Willebrand 
factor (VWF) were measured in plasma to assess whether endothelial inflammation was evident 
in young Fabry mice without experimental injury or other alteration. The serum levels of sVCAM-
1 were not different between WT and Gla null mice at 2 months (Figure 4 - 1A). However, 
sVCAM-1 was significantly elevated in Gla deficient mice at 12 months compared to the younger 
age of the same genotype and their age-matched WT mice. Intriguingly, plasma VWF level was 
significantly higher in 2 month old Gla null mice compared to WT mice (Figure 4 - 1B). Plasma 
VWF levels from Gla null mice at 5 and 17 months of age, but not WT mice, were significantly 
elevated in comparison with the same genotype at 2 months. It was previously observed that 
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microvascular dysfunction and eNOS uncoupling were evident at 2 months and exacerbated with 
age in these mice (23). These data indicated that Gla deficiency resulted in an age-dependent 
endothelial dysfunction and elevated VWF secretion into the circulation. Further experiments were 
next performed to probe the mechanism for the enhanced secretion of VWF in the setting of GLA 
deficiency.  
 
VWF gene expression 
VWF mRNA levels were next measured. In mouse, the lung expresses the highest level of VWF 
mRNA, and therefore, is the primary organ responsible for the circulating VWF antigen level (62). 
Lung homogenates from WT and Gla null mice were analyzed for VWF gene expression. No 
difference in VWF mRNA levels was observed between the Gla deficient mice and the WT mice 
by qRT-PCR analyses (Figure 4 - 2A, WT vs GLA null; 1.02 ± 0.12 vs 0.97 ± 0.15 arbitrary unit). 
In addition, VWF mRNA levels did not differ in the liver homogenates between WT and GLA 
null mice (Figure 4 - 2B, WT vs GLA null; 1.00 ± 0.24 vs 1.08 ± 0.17 arbitrary unit). Thus, these 
results suggested that the elevated VWF level in Gla deficient mice was not due to increased VWF 
production from these sites. 
 
Elevated VWF secretion in cells with GLA knockdown 
An established in vitro model of Fabry disease was employed to explore whether GLA deficiency 
directly promotes VWF secretion from the endothelial cells (49). We first determined the 
expression of VWF in the EA.hy926 human endothelial cell line. A positive linear relationship 
was confirmed between VWF level and the number of cells (r2 = 0.9242). The effect of GLA 
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disruption on WPB exocytosis was next characterized by RNA interference in these cells. After 
GLA siRNA treatment, GLA expression was decreased to a level not detected by western blotting 
while GAPDH expression was unaffected (Figure 4 - 3A). Cells were then incubated in 2% serum 
media under control siRNA (siSCR) or GLA siRNA (siGLA) conditions for three days to measure 
the amount of VWF released into the media. An almost 3-fold increase in the VWF level was 
observed by ELISA in the supernatants from siGLA compared with that of siSCR (Figure 4 - 3B). 
These data demonstrate that the loss of GLA directly results in the release of VWF from endothelial 
cells consistent with the increased plasma VWF levels observed in knockout mice. 
 
Decreased eNOS activity and inhibition of VWF secretion with NO provision in GLA knockdown 
cells 
Because GLA deficiency results in less NO production from this endothelial cell line due to lower 
eNOS activity (49), studies were performed to assess whether the elevated VWF secretion was 
associated with decreased NO bioavailability. Consistent with previous reports (47, 49), eNOS 
activity was significantly lower in siGLA than siSCR (Figure 4 - 4A). Because NO inhibits VWF 
secretion (27), siRNA-treated cells were incubated in the presence or absence of an exogenous NO 
donor, DETA-NONOate. In contrast to control conditions, the supplemental provision of NO (50 
µM) resulted in a 35% reduction in VWF secretion in siGLA cells (Figure 4 - 4B).  
 
Elevated VWF secretion in a permanent GLA deficient cell line by CRISPR/Cas9 
A previous study reported that VWF secretion is dependent on cell density as well as the duration 
of cell culture (26). Because siRNA treatments do not persist for more than three days, and the 
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efficiency of the transfection is dependent on cell seeding density (data not shown), a permanent 
GLA deficient cell line was generated to avoid confounding factors such as confluency and a 
transient effect of the siRNA interference. GLA activity level was first measured in this cell line. 
As expected, the enzyme activity was not detectable in CRISPR GLA cells (CR-GLA) as 
compared to that from CRISPR WT cells (CR-WT) (Figure 4 - 5A). Next, these cells were grown 
until confluent, and replaced with 2% serum media. VWF levels were measured in the media of 
CR-WT and CR-GLA over a more extended period of 96 hrs. VWF levels, measured by ELISA, 
were higher at the 12 hr time point and significantly elevated at the 24 hr time point (Figure 4 - 
5B). In additional sets of experiments, an approximately 4.7-fold increase in the level of VWF was 
observed in the media from CR-GLA compared to CR-WT cells at 48 hr and 72 hr time points 
(Figure 4 - 5C). It was next tested whether exogenous NO inhibits VWF secretion in CRISPR cells. 
Compared to the siRNA treated cells, CRISPR cells were viable at higher concentrations of 
exogenous NO (data not shown). Provision of 100 µM of NO donor for 3 days significantly 
decreased VWF secretion from both CR-WT and CR-GLA cells (Figure 4 - 5D). Surprisingly, 
VWF level from CR-GLA was completely normalized to the level seen in CR-WT vehicle treated 
cells with 100 µM of NO.  
VWF mRNA level was slightly, but significantly increased in CR-GLA in comparison with CR-
WT by qRT-PCR analysis (Figure 4 - 6A, CR-WT vs CR-GLA; 1.00 ± 0.02 vs 1.23 ± 0.14 arbitrary 
unit, p<0.01). The levels of IL-8, another component of WPBs, were also measured to confirm that 
elevated VWF secretion in GLA deficiency was due to enhanced WPB exocytosis. The IL-8 
concentration was significantly higher in the media of CR-GLA when compared with that of CR-
WT (Figure 4 - 6B, CR-WT vs CR-GLA; 544.8 ± 15.2 vs 1086.7 ± 23.5 pg/mL) consistent with 
increased WPB exocytosis. Together, these data reinforced the prior observations that GLA 
85 
 
deficiency promotes VWF secretion and exogenous NO inhibits the release. Since CRISPR cells 
were more stable for pharmacologic studies in comparison with the siRNA-treated cells, this cell 
line was used in subsequent studies. 
 
Sepiapterin treatment in CR-GLA 
eNOS protein expression in CR-GLA and CR-WT cells was next analyzed. Consistent with the 
previous finding in cultured primary aortic endothelial cells from Gla null mice (47), a greater than 
50% reduction in the eNOS expression of CR-GLA was observed compared with that of CR-WT 
(Figure 4 - 7A). Previously, a robust elevation of 3-nitrotyrosine was observed in GLA deficient 
cells, a marker of reactive nitrogen species produced in the presence of eNOS uncoupling (49). An 
attempt was made to “recouple” eNOS activity with sepiapterin treatment in CR-GLA cells. The 
activity of eNOS from CR-WT and CR-GLA was increased with sepiapterin in a dose-dependent 
manner (Figure 4 - 7B). However, eNOS activity of CR-GLA was approximately 50% lower than 
that of CR-WT at any given doses of sepiapterin. Nevertheless, eNOS activity of CR-GLA was 
2.5-fold higher with 300 µM sepiapterin than that of CR-WT vehicle condition (Figure 4 - 7B). 
Because exogenous NO treatment inhibited VWF secretion (Figure 4 - 5D), it was next examined 
whether increased endogenous NO production resulting from activating eNOS with sepiapterin 
decreases VWF exocytosis. Three days of sepiapterin (300 µM) treatment reduced VWF secretion 
from CR-GLA to the level of CR-WT control conditions (Figure 4 - 7C), similar to the effect of 
the exogenous NO donor. Nevertheless, the level of VWF with sepiapterin treatment in CR-GLA 
remained significantly higher than that of CR-WT, presumably due to the lower level of eNOS 
activity compared to CR-WT with 300 µM sepiapterin (Figure 4 - 7D). Endothelial-derived NO 
regulates vascular function, in part, through a soluble guanylate cyclase (sGC) and cyclic 
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guanosine monophosphate (cGMP) signaling pathway (39). However, the inhibition of sGC by a 
specific irreversible inhibitor, ODQ, did not modify the effects of the NO donor and sepiapterin 
on VWF release in CR-WT and CR-GLA cells (Figure 4 - 8). Together, these data indicate that 
both exogenous and endogenous NO repletion inhibit increased VWF release via a sGC/cGMP-
independent signaling pathway in the setting of GLA deficiency.  
 
Changes in SNO-NSF level in siGLA and CR-GLA cells 
A previous study from Matsushita and colleagues reported that NO inhibits WPB exocytosis 
through NSF S-nitrosylation (SNO-NSF) (30). In addition to NO, thioredoxin-1 is known to 
regulate VWF secretion by denitrosylating SNO-NSF in endothelial cells (19). Having 
characterized that GLA deficiency resulted in decreased NO production and increased VWF 
secretion (Figures 4 - 4, 5, and 7), it was next determined whether elevated VWF secretion is 
associated with decreased level of SNO-NSF in the setting of GLA deficiency. The siRNA-treated 
and the CRISPR cells were subjected to a biotin switch assay. Immunoblotting analyses of isolated 
biotin-labeled proteins showed approximately 75% higher level of SNO-NSF in siGLA compared 
to siSCR cells (Figure 4 - 9A). In addition, a 12% lower level of TRX-1 was associated with 
increased SNO-NSF in the siGLA compared to siSCR cells (Figure 4 -9B). Consistent with the 
findings in siRNA-treated cells, CR-GLA had approximately 50% higher and 24% lower levels of 
SNO-NSF and TRX-1, respectively, than those in CR-WT cells (Figure 4 - 9C and 9D). Together, 
these data showed that GLA deficiency resulted in increased SNO-NSF level and decreased TRX-




Antioxidant treatments in CR-GLA cells 
Decreased eNOS expression, reduced enzymatic activity, and deactivation of NO by reactive 
oxygen species can decrease NO bioavailability. Based on the previous finding that GLA 
deficiency elevated reactive oxygen species (44), it was evaluated whether decreasing ROS could 
lower VWF levels. CR-WT and CR-GLA cells were grown to confluence in the presence of 
ebselen (10 µM) or TEMPOL (1mM), glutathione peroxidase-1 and superoxide dismutase 
mimetics, respectively. After cell confluency was attained, the media was replaced with 2% serum 
containing media with one of the treatments or vehicle. The ebselen treatment for 3 days 
significantly reduced VWF secretion in both CR-WT and CR-GLA cells compared to their vehicle 
conditions (Figure 4 - 10A). In addition, the treatment in CR-GLA decreased VWF level below 
the level of CR-WT vehicle condition. Three days of TEMPOL incubation resulted in decreased 
VWF level in CR-GLA to a similar level of CR-WT vehicle condition (Figure 4 - 10B). However, 
the level of VWF in CR-GLA after the treatment remained significantly higher in comparison with 
CR-WT with TEMPOL incubation. These data are consistent with the interpretation that GLA 
deficiency elevates VWF secretion, in part, through increased production of ROS.  
 
Recombinant human GLA and eliglustat treatment 
Previously it was shown that 2 days of recombinant human GLA (α-Gal A) treatment lowered Gb3 
in Gla null mouse aortic endothelial cells (46). When eNOS activity was examined in a subsequent 
study, the reduction of Gb3 by the potent glucosylceramide synthase inhibitor, eliglustat, failed to 
restore the decreased eNOS activity significantly in these cells (47). The effects of recombinant α-
Gal A and eliglustat were evaluated to examine whether GLA deficiency per se or elevated globo-
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series glycosphingolipids was the primary cause for the elevated secretion of VWF. The CRISPR 
cells were pre-treated with α-Gal A (10 µg/mL) or eliglustat (200 nM) for 2 days prior to becoming 
confluent. After the pre-treatment, fresh low serum media with α-Gal A or eliglustat was used and 
VWF accumulation in the media measured over 3 days. VWF levels were no different with or 
without the enzyme treatment in CR-WT cells (Figure 4 - 11A). In CR-GLA, exogenous α-Gal A 
reduced VWF secretion by 18% on average in CR-GLA compared to vehicle controls, but this did 
not reach statistical significance (p=0.13). On the other hand, eliglustat treatment slightly, but 
significantly increased VWF secretion from both CR-WT and CR-GLA cells (Figure 4 - 11B). 
 
Discussion 
In this study, we report that GLA deficiency decreases eNOS activity and promotes VWF secretion 
in a mouse model and two in vitro models, identifying a potential mechanism for the vascular 
involvement in Fabry disease. Furthermore, pharmacological approaches that increase NO 
bioavailability or decrease ROS completely normalize VWF levels in an in vitro model of GLA 
deficiency. However, recombinant human GLA only partially decreases VWF secretion, while the 
inhibition of glycosphingolipid synthesis results in an increase in VWF secretion in vitro. Together, 
these results suggest that GLA deficiency may promote VWF secretion through decreased NO 
bioavailability and elevated ROS, but this abnormality is not readily reversed by normalization of 
glycosphingolipid levels.  
Clinical observations have revealed a high incidence of thrombosis and stroke in Fabry patients 
(50, 52) and a highly robust sensitivity to inducible thrombogenesis in murine models of Fabry 
disease (13, 45). VWF may contribute to the pathogenesis of thrombosis and atherosclerosis in 
Fabry disease due to its role in the formation of platelet thrombi (41). For example, studies using 
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mouse models of atherosclerosis have demonstrated that platelet adhesion to plaque-prone sites is 
inhibited by inactivation of VWF or platelet glycoprotein Ib, a receptor for VWF (29, 51). VWF 
is selectively expressed in WPBs in endothelial cells and α-granules in platelets (20, 34). However, 
recent studies employing chimeric mice whose VWF was restricted to either endothelial cells or 
platelets demonstrated that endothelial-derived VWF is a major determinant for thrombus 
formation (22, 35).  
Numerous studies have documented abnormal procoagulant and proinflammatory profiles in Fabry 
patients (6, 7, 10, 54). Only three studies have reported measurements of VWF levels in this group. 
In two reports, VWF levels were not different or only slightly elevated in Fabry patients when 
compared to their control groups (10, 54). In a third study, a significant elevation of VWF in both 
hemizygous males and heterozygous female carriers (36). The failure to report consistent 
elevations of VWF in the Fabry population may reflect the small numbers of patients studied, the 
inclusion of treated and untreated patients in the patients studied, or differences in the analytical 
methods employed for VWF measurements. More recently, in an initiative to identify biomarkers 
in large cohorts of untreated pediatric and adult male Fabry patients, VWF was observed to be 
significantly elevated in both groups (Kevin Mills, UCL Institute of Child Health, unpublished 
data). 
Early studies addressed the observation that Gla null mice lacked a spontaneous vascular 
phenotype. Three inducible models of vascular disease were identified including arterial 
thrombosis following intravascular oxidant release from rose Bengal, accelerated atherosclerosis 
in Gla null mice bred on an apoE null background, and impaired vasorelaxation in pre-contracted 
aortic and mesenteric rings exposed to acetylcholine (8, 13, 23, 38). Subsequent studies in primary 
cultures of aortic endothelial cells from Gla null mice demonstrated the accumulation of Gb3 in 
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caveolar fractions in association with impaired oligomerization of caveolin-1 (48). These structural 
changes were associated with decreased eNOS expression and activity (47). Based on these prior 
studies, we hypothesize eNOS dysregulation may be the basis for relationship between GLA 
deficiency and increased VWF secretion in the current studies. 
Generally speaking, eNOS dysregulation refers to one of three distinct changes. These include 
decreased NO bioavailability, eNOS uncoupling resulting in elevated reactive nitrogen species, 
and alterations in NO-mediated post-translational protein modification, such as S-nitrosylation. 
Each of these mechanisms was considered. 
Matsushita et al. proposed a mechanism whereby NO inhibits WPB exocytosis by inactivation of 
a vesicle-membrane fusion protein, NSF (30). NO has been shown to nitrosylate cysteine residues 
of NSF, which blocks NSF disassembly activity of SNARE complex (30). In the current study, 
however, the inhibitory role of SNO-NSF was not associated with elevated VWF secretion in our 
in vitro models. Rather, we observed that the elevated SNO-NSF was associated with decreased 
TRX-1 levels, a reductase in the endothelial cells (19). Therefore, the observed SNO-NSF level 
may not determine NO availability in the setting of Fabry disease.  
Several studies have reported an inverse association between flow-mediated vasodilation and 
plasma VWF levels (16, 25). We have observed that eNOS activity was reduced in endothelial 
cells following GLA disruption consistent with our previous study (49). NO bioavailability was 
increased with DETA-NONOate and sepiapterin treatments. Increasing NO by either exogenous 
or endogenous means  was sufficient to normalize the elevated VWF release in GLA-deficient 
cells, suggesting the increased VWF secretion was secondary to decreased NO level in this setting.  
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The uncoupling of eNOS has been associated with elevated reactive oxygen and nitrogen species 
in experimental models and clinical samples from Fabry patients (6, 44, 49). ROS, inflammatory 
cytokines, and mediators of inflammation induce VWF secretion in endothelial cells (4, 5, 31, 56, 
60). In agreement with these observations, we observed that antioxidant treatment with tempol and 
ebselen negated the effect of GLA deficiency on enhanced VWF release.  
Disruption of GLA or Gb3 loading has been shown to promote decreased eNOS activity and ROS 
production (44, 49). eNOS is then uncoupled and becomes a source of superoxide and peroxynitrite 
(15). Under this condition, removing Gb3 by ERT or substrate reduction may not be sufficient to 
“recouple” eNOS. This hypothesis is substantiated by a previous observation that reduction of Gb3 
in primary aortic endothelial cells of Gla null mice did not significantly restore eNOS activity (47). 
In the current study, providing human recombinant GLA back to GLA-null cells only partially 
decreased VWF secretion, suggesting that the GLA deficient-endothelial cells remained activated. 
Surprisingly, inhibition of glucosylceramide synthase with eliglustat slightly, but significantly 
increased VWF secretion despite decreasing globo-series glycosphingolipids (unpublished data). 
While the basis for inability of these treatments to reverse the VWF secretion is not clear, these 
findings may be relevant to the continued occurrence of strokes in advanced patients with ERT 
and will require further study (2, 59). 
In summary, the findings from this study are significant for several reasons. First, there is currently 
a paucity of biomarkers available to specifically assess endothelial dysfunction in Fabry disease. 
Second, cerebrovascular events continue to occur in Fabry patients receiving enzyme replacement 
therapy, suggesting that the underlying vasculopathy may not be completely corrected by enzyme 
replacement and reduction of Gb3 alone. Finally, an elevated urinary Gb3 is associated with near-
term mortality in heart disease patients in the absence Fabry disease (42). Therefore, observations 
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from the current study may support a pathophysiologic link between glycosphingolipid 
metabolism and vascular disease with relevance to a broader population. Future studies on 
enhanced VWF release as a predictor of stroke and myocardial infarction, particularly in Fabry 
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Figure 4 - 1. Age-dependent endothelial activation in mice with Fabry disease 
The blood was drawn via the retro-orbital plexus from male wild type and Gla deficient mice at 
the indicated ages. A. Levels of soluble VCAM-1 were measured by ELISA (n=5-10/group). *p 
< 0.05 compared to the age-matched WT mice, †p < 0.001 compared to the same genotype at 2 
months. B. Circulating plasma VWF levels were measured by AlphaLISA method as described 
in the method section (n=4-8 in each age group). A dilution series of pooled platelet-poor plasma 
(PPP) from C56BL/6 mice (n=10) was used as a reference (100%). *p < 0.05 compared to the 








Figure 4 - 2. VWF gene expression in the lung and the liver in WT and Gla deficient mice 
A. Expression of mRNA for VWF in the lung homogenates of WT and Gla deficient mice at 10 
months. mRNA was determined using real-time PCR, normalized to GAPDH, and expressed 
relative to the level in WT lung (n=4/group).  B.  Expression of mRNA for VWF in the liver 
homogenates of WT and Gla deficient mice at 10 months. mRNA was determined using real-






Figure 4 - 3. Elevated VWF secretion in EA.hy926 cells following GLA knockdown 
A. Representative western blot showing the knockdown efficiency of siRNA against GLA in 
EA.hy926 cells. B. Cells were transfected with SCR or GLA siRNA. After the second 
transfection, the transfection media were replaced with 2% serum media and incubated for 3 
days. Levels of VWF accumulation in the media were determined by ELISA using a dilution 
series of pooled normal plasma with known VWF antigen levels as standards and expressed as 








Figure 4 - 4. Decreased NO production and suppression of VWF secretion by an exogenous 
NO donor, DETA-NONOate 
A. The cells were collected after the siRNA transfection. Endothelial nitric oxide synthase 
activity was measured by monitoring the conversion from radiolabeled L-arginine to the 
formation of L-citrulline. The activity was expressed as L-citrulline count per minute (cpm), and 
normalized to each sample’s total protein level (n=6/group) *p < 0.0001. B. After the 
transfection, cells were incubated with vehicle (10 mM HEPES) or DETA-NONOate (50 µM) 
for 3 days. VWF levels in the cell culture supernatants were determined by ELISA and expressed 
as fold changes with respect to siSCR vehicle (n=4/group). *p < 0.01 compared to siSCR 






Figure 4 - 5. Time course basal VWF secretion from CRISPR WT and GLA deficient cells 
A. An equal amount of protein (3 µg) from cell lysates was used. GLA activity in lysates from 
CR-WT and CR-GLA was expressed as mmol/mg protein per hr PNP released (n=6/group). 
N.D.: not detectable. B. Normal growth media were replaced with 2% serum media after 
confluency. The cell culture supernatants were collected at the various time points thereafter 
(n=4/group). VWF levels were expressed as fold changes with respect to CR-WT at 12 hr. C. 
VWF secretion after 2-3 days (n=11/group). *p<0.00001. D. After confluency, cells were 
incubated with vehicle (10 mM HEPES) or DETA-NONOate (100 µM) for 3 days. VWF levels 
in the cell culture supernatants were determined by ELISA and expressed as fold changes with 
respect to CR-WT vehicle (n=8/group). †p < 0.001 compared to vehicle in the same group, *p 











Figure 4 - 6. VWF mRNA and IL-8 levels in CRISPR cells 
A. Expression of mRNA for VWF in CR-WT and CR-GLA cells. mRNA was determined using 
real-time PCR, normalized to TATA-binding protein, and expressed relative to the level in CR-







Figure 4 - 7. eNOS dysregulation and sepiapterin treatment in CRISPR WT and GLA cells 
A. An equal amount of protein (30 µg) from CR-WT and CR-GLA cells was separated on 4-
12% SDS PAGE (n=9/group). *p < 0.00001. B. Cells were incubated with vehicle (DMSO) or 
various concentrations of sepiapterin for 24 hours. Trypsinized cells were pelleted and subjected 
to eNOS activity assay. eNOS activity was determined as described in Figure 4 - 4A. The data 
are an average of triplicate assays from two separate sets of samples. C. After confluency, cells 
were incubated with vehicle (DMSO) or sepiapterin (300 µM) for 3 days. VWF levels in the cell 
culture supernatants were determined by ELISA and expressed as fold changes with respect to 
CR-WT vehicle (n=4/group). p = 0.01 between CR-WT vehicle and CR-GLA with sepiapterin, 
†p < 0.001 compared to vehicle in the same group, *p < 0.0001 compared to CR-WT vehicle, 
‡p < 0.0001 compared to CR-WT with sepiapterin. D.  After confluency, cells were incubated 
with vehicle (DMSO) or sepiapterin (300 µM) for 3 days. These cells were trypsinized and 
subjected to eNOS activity assay as described above (n=4/group). †p < 0.001 compared to 
vehicle in the same group, *p < 0.001 compared to CR-WT vehicle, ‡p < 0.001 compared to 









Figure 4 - 8. Effects of ODQ on VWF secretion in CR-WT and CR-GLA cells treated with 
DETA-NONOate and sepiapterin 
A. CR-WT and CR-GLA cells were seeded in a 24-well plate. Cells were incubated with or 
without DETA-NONOate (100 µM) and/or the sGC inhibitor ODQ (5 µM). ODQ was added 1 
hr prior to the addition of DETA-NONOate to inhibit the activation of sGC by NO. VWF levels 
in the cell culture supernatants were determined by ELISA and expressed as fold changes with 
respect to CR-WT vehicle (n=4/group). *p < 0.01 compared to WT vehicle, †p < 0.05 compared 
to vehicle in the same group. B. Cells were treated as described above with or without sepiapterin 
(300 µM) and/or ODQ (5 µM). VWF levels in the cell culture supernatants were determined by 
ELISA and expressed as fold changes with respect to CR-WT vehicle (n=4/group). *p < 0.01 
compared to CR-WT vehicle, †p < 0.01 compared to vehicle in the same group, ‡p < 0.01 






Figure 4 - 9. Increased NSF S-nitrosylation and decreased TRX-1 in GLA deficient cells 
A. EA.hy926 cells treated with siSCR or siGLA were subjected to the biotin switch assay as 
described in the methods section. Isolated biotin-labeled proteins were separated on 4-12% SDS 
PAGE. The level of S-nitroyslation of NSF was normalized to its total protein level (n=6/group). 
*p < 0.02. B. An equal amount of protein from siRNA treated cells was loaded and separated 
on SDS PAGE (n=6/group). *p < 0.05. C. Confluent CR-WT and CR-GLA cells were subjected 
to the biotin switch assay. Isolated biotin-labeled proteins were separated on 4-12% SDS PAGE. 
The level of S-nitroyslation of NSF was normalized to its total protein level (n=6/group). *p < 
0.001. D.  An equal amount of protein from CR-WT and CR-GLA cells was loaded and 







Figure 4 - 10. Decrease in VWF secretion with antioxidant treatments in CRISPR cells 
A. After confluency, cells were incubated with vehicle (DMSO 0.2%) or ebselen (10 µM) for 3 
days. VWF levels in the cell culture supernatants were determined by ELISA and expressed as 
fold changes with respect to CR-WT vehicle (n=6/group). p = 0.0001 between CR-WT vehicle 
and CR-GLA with ebselen, †p < 0.0001 compared to vehicle in the same group, *p < 0.0001 
compared to CR-WT vehicle, ‡p < 0.05 compared to CR-WT with ebselen. B. After confluency, 
cells were incubated with vehicle or Tempol (1 mM) for 3 days. VWF levels in the cell culture 
supernatants were determined by ELISA and expressed as fold changes with respect to CR-WT 
vehicle (n=6/group). †p < 0.0001 compared to vehicle in the same group, *p < 0.0001 compared 







Figure 4 - 11. Treatment of CR-WT and CR-GLA cells with recombinant human α-
galactosidase A and eliglustat 
A. CR-WT and CR-GLA cells were seeded in a 24-well plate. Next day, vehicle (25 mM Tris 
and 150 mM NaCl, pH 7.5) or recombinant human GLA (10 µg/mL, α-Gal A) was added to 
each well. After 2 days of the treatment, the medium was replaced with 2% serum medium 
containing vehicle or α-Gal A and incubated for 3 days. VWF levels were determined by ELISA 
and expressed as fold changes with respect to CR-WT vehicle (n=6-10/group). p=0.13 between 
vehicle- and α-Gal A-treated CR-GLA; *p < 0.00001 compared to CR-WT vehicle. B. CR-WT 
and CR-GLA cells were seeded in a 24-well plate. The following day, vehicle (DMEM media) 
or Eliglustat (200 nM) was added to each well. After 2 days of the treatment, the medium was 
replaced with 2% serum medium containing vehicle or eliglustat and incubated for additional 3 
days. VWF levels were determined by ELISA and expressed as fold changes with respect to CR-








1. Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, 
van Roomen C, Mirzaian M, Wijburg FA, Linthorst GE, Vedder AC, Rombach SM, 
Cox-Brinkman J, Somerharju P, Boot RG, Hollak CE, Brady RO, and Poorthuis BJ. 
Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proceedings of the 
National Academy of Sciences of the United States of America 105: 2812-2817, 2008. 
 
2. Beck M, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C, Linhart A, 
Sunder-Plassmann G, Houge G, Ramaswami U, Gal A, and Mehta A. Fabry disease: 
overall effects of agalsidase alfa treatment. European journal of clinical investigation 34: 
838-844, 2004. 
 
3. Benjamin ER, Flanagan JJ, Schilling A, Chang HH, Agarwal L, Katz E, Wu X, Pine 
C, Wustman B, Desnick RJ, Lockhart DJ, and Valenzano KJ. The pharmacological 
chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry 
patient cell lines. Journal of inherited metabolic disease 32: 424-440, 2009. 
 
4. Bernardo A, Ball C, Nolasco L, Moake JF, and Dong JF. Effects of inflammatory 
cytokines on the release and cleavage of the endothelial cell-derived ultralarge von 
Willebrand factor multimers under flow. Blood 104: 100-106, 2004. 
 
5. Bhatia R, Matsushita K, Yamakuchi M, Morrell CN, Cao W, and Lowenstein CJ. 
Ceramide triggers Weibel-Palade body exocytosis. Circulation research 95: 319-324, 2004. 
 
6. Biancini GB, Jacques CE, Hammerschmidt T, de Souza HM, Donida B, Deon M, 
Vairo FP, Lourenço CM, Giugliani R, and Vargas CR. Biomolecules damage and redox 
status abnormalities in Fabry patients before and during enzyme replacement therapy. 
Clinica Chimica Acta 461: 41-46, 2016. 
 
7. Biancini GB, Vanzin CS, Rodrigues DB, Deon M, Ribas GS, Barschak AG, 
Manfredini V, Netto CB, Jardim LB, Giugliani R, and Vargas CR. 
Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry 
patients treated with enzyme replacement therapy. Biochimica et biophysica acta 1822: 
226-232, 2012. 
 
8. Bodary PF, Shen Y, Vargas FB, Bi X, Ostenso KA, Gu S, Shayman JA, and Eitzman 
DT. Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with 
apolipoprotein E deficiency. Circulation 111: 629-632, 2005. 
 
9. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, and Laster L. 





10. DeGraba T, Azhar S, Dignat-George F, Brown E, Boutiere B, Altarescu G, McCarron 
R, and Schiffmann R. Profile of endothelial and leukocyte activation in Fabry patients. 
Annals of neurology 47: 229-233, 2000. 
 
11. Desch KC, Ozel AB, Siemieniak D, Kalish Y, Shavit JA, Thornburg CD, 
Sharathkumar AA, McHugh CP, Laurie CC, Crenshaw A, Mirel DB, Kim Y, Cropp 
CD, Molloy AM, Kirke PN, Bailey-Wilson JE, Wilson AF, Mills JL, Scott JM, Brody 
LC, Li JZ, and Ginsburg D. Linkage analysis identifies a locus for plasma von 
Willebrand factor undetected by genome-wide association. Proceedings of the National 
Academy of Sciences of the United States of America 110: 588-593, 2013. 
 
12. Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, Grabowski 
G, Packman S, and Wilcox WR. Fabry disease, an under-recognized multisystemic 
disorder: expert recommendations for diagnosis, management, and enzyme replacement 
therapy. Ann Intern Med 138: 338-346, 2003. 
 
13. Eitzman DT, Bodary PF, Shen Y, Khairallah CG, Wild SR, Abe A, Shaffer-Hartman 
J, and Shayman JA. Fabry disease in mice is associated with age-dependent susceptibility 
to vascular thrombosis. J Am Soc Nephrol 14: 298-302, 2003. 
 
14. Eng CM and Desnick RJ. Molecular basis of Fabry disease: mutations and 
polymorphisms in the human alpha-galactosidase A gene. Hum Mutat 3: 103-111, 1994. 
 
15. Forstermann U. Nitric oxide and oxidative stress in vascular disease. Pflugers Archiv : 
European journal of physiology 459: 923-939, 2010. 
 
16. Freestone B, Chong AY, Nuttall S, and Lip GY. Impaired flow mediated dilatation as 
evidence of endothelial dysfunction in chronic atrial fibrillation: relationship to plasma von 
Willebrand factor and soluble E-selectin levels. Thrombosis research 122: 85-90, 2008. 
 
17. Gelderman MP, Schiffmann R, and Simak J. Elevated Endothelial Microparticles in 
Fabry Children Decreased After Enzyme Replacement Therapy. Arteriosclerosis, 
thrombosis, and vascular biology 27: e138-e139, 2007. 
 
18. Germain DP. Fabry disease. Orphanet journal of rare diseases 5: 30, 2010. 
 
19. Ito T, Yamakuchi M, and Lowenstein CJ. Thioredoxin increases exocytosis by 
denitrosylating N-ethylmaleimide-sensitive factor. The Journal of biological chemistry 
286: 11179-11184, 2011. 
 
20. Jaffe EA, Hoyer LW, and Nachman RL. Synthesis of antihemophilic factor antigen by 
cultured human endothelial cells. The Journal of clinical investigation 52: 2757-2764, 
1973. 
 
21. Jaffrey SR and Snyder SH. The biotin switch method for the detection of S-nitrosylated 




22. Kanaji S, Fahs SA, Shi Q, Haberichter SL, and Montgomery RR. Contribution of 
platelet vs. endothelial VWF to platelet adhesion and hemostasis. Journal of thrombosis 
and haemostasis : JTH 10: 1646-1652, 2012. 
 
23. Kang JJ, Shu L, Park JL, Shayman JA, and Bodary PF. Endothelial nitric oxide 
synthase uncoupling and microvascular dysfunction in the mesentery of mice deficient in 
α-galactosidase A. American journal of physiology Gastrointestinal and liver physiology 
306: G140-G146, 2014. 
 
24. Keefer LK, Nims RW, Davies KM, and Wink DA. "NONOates" (1-substituted diazen-
1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms. Methods 
in enzymology 268: 281-293, 1996. 
 
25. Lee KW, Blann AD, and Lip GY. High pulse pressure and nondipping circadian blood 
pressure in patients with coronary artery disease: Relationship to thrombogenesis and 
endothelial damage/dysfunction. American journal of hypertension 18: 104-115, 2005. 
 
26. LoMonaco MB and Lowenstein CJ. Enhanced assay of endothelial exocytosis using 
extracellular matrix components. Analytical biochemistry 452: 19-24, 2014. 
 
27. Lowenstein CJ. Nitric oxide regulation of protein trafficking in the cardiovascular system. 
Cardiovascular research 75: 240-246, 2007. 
 
28. MacDermot KD, Holmes A, and Miners AH. Anderson-Fabry disease: clinical 
manifestations and impact of disease in a cohort of 60 obligate carrier females. Journal of 
medical genetics 38: 769-775, 2001. 
 
29. Massberg S, Brand K, Gruner S, Page S, Muller E, Muller I, Bergmeier W, Richter 
T, Lorenz M, Konrad I, Nieswandt B, and Gawaz M. A critical role of platelet adhesion 
in the initiation of atherosclerotic lesion formation. The Journal of experimental medicine 
196: 887-896, 2002. 
 
30. Matsushita K, Morrell CN, Cambien B, Yang SX, Yamakuchi M, Bao C, Hara MR, 
Quick RA, Cao W, O'Rourke B, Lowenstein JM, Pevsner J, Wagner DD, and 
Lowenstein CJ. Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimide-
sensitive factor. Cell 115: 139-150, 2003. 
 
31. Matsushita K, Morrell CN, Mason RJ, Yamakuchi M, Khanday FA, Irani K, and 
Lowenstein CJ. Hydrogen peroxide regulation of endothelial exocytosis by inhibition of 
N-ethylmaleimide sensitive factor. The Journal of cell biology 170: 73-79, 2005. 
 
32. Mayes JS, Scheerer JB, Sifers RN, and Donaldson ML. Differential assay for lysosomal 
alpha-galactosidases in human tissues and its application to Fabry's disease. Clinica 




33. Morange PE, Simon C, Alessi MC, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans 
A, Ducimetiere P, Juhan-Vague I, and Group PS. Endothelial cell markers and the risk 
of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction 
(PRIME) study. Circulation 109: 1343-1348, 2004. 
 
34. Nachman R, Levine R, and Jaffe EA. Synthesis of factor VIII antigen by cultured guinea 
pig megakaryocytes. The Journal of clinical investigation 60: 914-921, 1977. 
 
35. Nichols TC, Samama CM, Bellinger DA, Roussi J, Reddick RL, Bonneau M, Read 
MS, Bailliart O, Koch GG, Vaiman M, and et al. Function of von Willebrand factor after 
crossed bone marrow transplantation between normal and von Willebrand disease pigs: 
effect on arterial thrombosis in chimeras. Proceedings of the National Academy of Sciences 
of the United States of America 92: 2455-2459, 1995. 
 
36. O'Donnell J, Hughes D, Riddell A, Brown S, Richfield L, and Mehta A. Marked 
elevation of plasma von Willebrand factor antigen levels in hemizygous males with Fabry 
disease. Acta Pædiatrica 91: 130, 2002. 
 
37. Ohshima T, Murray GJ, Swaim WD, Longenecker G, Quirk JM, Cardarelli CO, 
Sugimoto Y, Pastan I, Gottesman MM, Brady RO, and Kulkarni AB. alpha-
Galactosidase A deficient mice: a model of Fabry disease. Proceedings of the National 
Academy of Sciences of the United States of America 94: 2540-2544, 1997. 
 
38. Park JL, Whitesall SE, D'Alecy LG, Shu L, and Shayman JA. Vascular dysfunction in 
the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based 
defect. Clin Exp Pharmacol Physiol 35: 1156-1163, 2008. 
 
39. Qian J, Zhang Q, Church JE, Stepp DW, Rudic RD, and Fulton DJ. Role of local 
production of endothelium-derived nitric oxide on cGMP signaling and S-nitrosylation. 
American journal of physiology Heart and circulatory physiology 298: H112-118, 2010. 
 
40. Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MGW, and Hollak 
CEM. Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, 
heart and brain. Orphanet journal of rare diseases 8: 47, 2013. 
 
41. Sadler JE. von Willebrand factor assembly and secretion. Journal of thrombosis and 
haemostasis : JTH 7: 24-27, 2009. 
 
42. Schiffmann R, Forni S, Swift C, Brignol N, Wu X, Lockhart DJ, Blankenship D, Wang 
X, Grayburn PA, Taylor MR, Lowes BD, Fuller M, Benjamin ER, and Sweetman L. 
Risk of death in heart disease is associated with elevated urinary globotriaosylceramide. 
Journal of the American Heart Association 3: e000394, 2014. 
 
43. Sestito S, Ceravolo F, and Concolino D. Anderson-Fabry disease in children. Current 




44. Shen JS, Meng XL, Moore DF, Quirk JM, Shayman JA, Schiffmann R, and Kaneski 
CR. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion 
molecule expression in Fabry disease endothelial cells. Molecular genetics and metabolism 
95: 163-168, 2008. 
 
45. Shen Y, Bodary PF, Vargas FB, Homeister JW, Gordon D, Ostenso KA, Shayman JA, 
and Eitzman DT. Alpha-galactosidase A deficiency leads to increased tissue fibrin 
deposition and thrombosis in mice homozygous for the factor V Leiden mutation. Stroke; 
a journal of cerebral circulation 37: 1106-1108, 2006. 
 
46. Shu L, Murphy HS, Cooling L, and Shayman JA. An in vitro model of Fabry disease. J 
Am Soc Nephrol 16: 2636-2645, 2005. 
 
47. Shu L, Park JL, Byun J, Pennathur S, Kollmeyer J, and Shayman JA. Decreased nitric 
oxide bioavailability in a mouse model of Fabry disease. J Am Soc Nephrol 20: 1975-1985, 
2009. 
 
48. Shu L and Shayman JA. Caveolin-associated accumulation of globotriaosylceramide in 
the vascular endothelium of alpha-galactosidase A null mice. The Journal of biological 
chemistry 282: 20960-20967, 2007. 
 
49. Shu L, Vivekanandan-Giri A, Pennathur S, Smid BE, Aerts JM, Hollak CE, and 
Shayman JA. Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry 
disease. Kidney Int 86: 58-66, 2014. 
 
50. Sims K, Politei J, Banikazemi M, and Lee P. Stroke in Fabry disease frequently occurs 
before diagnosis and in the absence of other clinical events: natural history data from the 
Fabry Registry. Stroke; a journal of cerebral circulation 40: 788-794, 2009. 
 
51. Theilmeier G, Michiels C, Spaepen E, Vreys I, Collen D, Vermylen J, and Hoylaerts 
MF. Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in 
response to hypercholesterolemia. Blood 99: 4486-4493, 2002. 
 
52. Utsumi K, Yamamoto N, Kase R, Takata T, Okumiya T, Saito H, Suzuki T, Uyama 
E, and Sakuraba H. High incidence of thrombosis in Fabry's disease. Internal medicine 
36: 327-329, 1997. 
 
53. van Schie MC, de Maat MP, Isaacs A, van Duijn CM, Deckers JW, Dippel DW, and 
Leebeek FW. Variation in the von Willebrand factor gene is associated with von 
Willebrand factor levels and with the risk for cardiovascular disease. Blood 117: 1393-
1399, 2011. 
 
54. Vedder AC, Biro E, Aerts JM, Nieuwland R, Sturk G, and Hollak CE. Plasma markers 
of coagulation and endothelial activation in Fabry disease: impact of renal impairment. 
Nephrology, dialysis, transplantation : official publication of the European Dialysis and 




55. Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. 
Journal of thrombosis and haemostasis : JTH 4: 1186-1193, 2006. 
 
56. Vischer UM, Jornot L, Wollheim CB, and Theler JM. Reactive oxygen intermediates 
induce regulated secretion of von Willebrand factor from cultured human vascular 
endothelial cells. Blood 85: 3164-3172, 1995. 
 
57. Weidemann F, Niemann M, Stork S, Breunig F, Beer M, Sommer C, Herrmann S, 
Ertl G, and Wanner C. Long-term outcome of enzyme-replacement therapy in advanced 
Fabry disease: evidence for disease progression towards serious complications. Journal of 
internal medicine 274: 331-341, 2013. 
 
58. Whybra C, Kampmann C, Willers I, Davies J, Winchester B, Kriegsmann J, Bruhl 
K, Gal A, Bunge S, and Beck M. Anderson-Fabry disease: clinical manifestations of 
disease in female heterozygotes. Journal of inherited metabolic disease 24: 715-724, 2001. 
 
59. Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, 
and Germain DP. Long-term safety and efficacy of enzyme replacement therapy for Fabry 
disease. Am J Hum Genet 75: 65-74, 2004. 
 
60. Xiang Y, Cheng J, Wang D, Hu X, Xie Y, Stitham J, Atteya G, Du J, Tang WH, Lee 
SH, Leslie K, Spollett G, Liu Z, Herzog E, Herzog RI, Lu J, Martin KA, and Hwa J. 
Hyperglycemia repression of miR-24 coordinately upregulates endothelial cell expression 
and secretion of von Willebrand factor. Blood 125: 3377-3387, 2015. 
 
61. Xiang Y and Hwa J. Regulation of VWF expression, and secretion in health and disease. 
Current opinion in hematology 23: 288-293, 2016. 
 
62. Yamamoto K, de Waard V, Fearns C, and Loskutoff DJ. Tissue distribution and 
regulation of murine von Willebrand factor gene expression in vivo. Blood 92: 2791-2801, 
1998. 
 
63. Yee A, Gildersleeve RD, Gu S, Kretz CA, McGee BM, Carr KM, Pipe SW, and 
Ginsburg D. A von Willebrand factor fragment containing the D'D3 domains is sufficient 








Voluntary wheel exercise training improves Akt/AMPK/eNOS signaling cascades, but not 
endothelial dysfunction in aged mice deficient in α-galactosidase A 
 
Abstract 
Fabry disease is caused by loss of activity of the lysosomal hydrolase α-galactosidase A (GLA). 
Premature life-threatening complications in Fabry patients arise from cardiovascular disease, 
including stroke and myocardial infarction. Exercise training has been shown to improve 
endothelial dysfunction in various settings including coronary artery disease. However, the effects 
of exercise training on endothelial dysfunction in Fabry disease have not been investigated. Gla 
knockout mice were single-housed in a cage equipped with a voluntary wheel (EX) or no wheel 
(SED) for 12 weeks. Exercised mice ran 10 km/day on average during the voluntary running 
intervention (VR) period. Despite significantly higher food intake in EX than SED, body weights 
of EX and SED remained stable during the VR period. After the completion of VR, citrate synthase 
activity in gastrocnemius muscle was significantly higher in EX than SED. Western blot analyses 
demonstrated that VR resulted in greater phosphorylation of Akt (S473) and AMPK (T172) in the 
aorta of EX compared to SED. Furthermore, VR significantly enhanced eNOS protein expression 
and phosphorylation at S1177 by 20% and 50% in the aorta of EX when compared with SED, 
suggesting eNOS activation. In contrast, anti- and pro-oxidative enzymes including superoxide 
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dismutase and p67 subunit of NADPH oxidase were not different between groups. Although the 
aortic endothelial relaxation to acetylcholine was slightly increased in EX, it did not reach 
statistical significance. Overall, this study provides the first evidence that VR improves 
Akt/AMPK/eNOS signaling cascades, but not endothelial function in the aorta of aged Gla 
deficient mice.  
 
Introduction 
Fabry disease is an X-linked lysosomal storage disorder that results from a defective or absent 
activity of α-galactosidase A (GLA) (8). The enzymatic defect leads to a progressive accumulation 
of glycosphingolipids including globotriaosylceramide, galabiosylceramide, and 
globotriaosylsphingosine. This toxic accumulation is observed in a variety of cell types, but 
especially found in the endothelium and smooth muscle cells (25, 35). Early symptoms of Fabry 
disease in childhood include episodic acute pain and gastrointestinal involvement with abdominal 
pain, diarrhea, and nausea (25). However, premature life-threatening complications arise from 
cardiovascular diseases around fourth decade of life, and include cerebrovascular events, 
myocardial infarction, hypertrophic cardiomyopathy, and renal failure (18). Whereas enzyme 
replacement therapy (ERT) with recombinant GLA is the only approved treatment for Fabry 
disease, there is no clear evidence that ERT alters the natural course of cardiovascular morbidities 
in patients with advanced Fabry disease (17).  
A mouse model of Fabry disease has been used to explore the vascular pathophysiology in the 
setting of GLA deficiency. Several inducible models of vasculopathy in these mice have 
demonstrated accelerated atherosclerosis, oxidant-induced occlusive arterial thrombosis, impaired 
acetylcholine-induced vascular relaxation, and the presence of endothelial nitric oxide synthase 
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(eNOS) uncoupling (4, 16, 30, 43). A potential link of these experimentally observed abnormalities 
is decreased nitric oxide (NO) bioavailability. Exercise has been shown to be one of the most 
effective non-pharmacological interventions for improving NO bioavailability (37). During the 
last two decades, the beneficial effects of exercise on the vascular endothelium have been 
extensively studied in various aspects including endothelium-dependent vasodilation, anti-
inflammation, and anti-atherosclerosis (7, 15, 46). Furthermore, exercise has been demonstrated 
to improve acetylcholine-mediated coronary blood flow even in the setting of documented 
coronary artery disease (26, 27), suggesting that the presence of advanced disease does not 
preclude improvements in endothelial function resulting from exercise. Although exercise 
intolerance has been reported in patients with Fabry disease previously (19), a more recent study 
showed that exercise training could improve exercise capacity and well-being of Fabry patients 
who refrained from physical activity in the past (45). This suggests that exercise training might be 
an alternative therapeutic option in Fabry disease. Yet, the benefits of exercise training with respect 
to vasculopathy in Fabry disease remain unclear.  
The purpose of the present study, therefore, was to directly assess the effects of 12 weeks of 
voluntary wheel exercise training on signaling and functional alterations in the aorta using an 
established mouse model of Fabry disease. Specifically, we focused on aortic endothelial function, 
selected enzymes influencing the NO bioavailability in the endothelium (AMPK, Akt, eNOS 
expression and S1177, superoxide dismutase, and the p67phox subunit of NADPH oxidase) and 






Gla null mice (129/SvJXC57BL/6J) used in this study were bred from mice originally generated 
and provided by Drs. Ashok Kulkarni and Roscoe Brady (National Institute of Health, Bethesda, 
MD) as described previously (42). These mice were back-crossed a minimum of six generations 
to the C57BL/6J strain. The animals were maintained on a 12-h light/dark cycle (0600 h to 1800 
h) with free access to food and water ad libitum. A week before the voluntary wheel intervention, 
groups of male mice (8-11 months) with similar average body weight were single-housed and 
assigned to either a control sedentary (n=20, SED) or voluntary wheel running group (n=20, EX). 
Mice in the EX group were provided with a running wheel (5” diameter x 2” width) equipped with 
an odometer (Bell Dashboard 100-F12) for 12 weeks. Running distance and food intake were 
monitored daily. Body weight was measured weekly. All animal experiments were conducted 
according to the protocol of the Institutional Animal Care and Use Committee of the University of 
Michigan.   
 
Tissue Harvest  
Animals in the EX group had access to the voluntary wheel up until the time of tissue collection. 
Mice were euthanized with an injection of pentobarbital sodium (66.5 mg/kg ip) at approximately 
0900 h.  Due to the logistics of the functional studies of the aorta, one mouse from each group was 
euthanized per day on consecutive days at the end of the 12-week intervention.   
 
Aortic protein expression 
The thoracic aorta was dissected, cleared of surrounding connective tissues in cold PSS, and frozen 
in liquid nitrogen. The vessels were pulverized in liquid nitrogen using a pestle. Each powdered 
sample was lysed with 200 µl RIPA lysis buffer (#R0278, Sigma) with 1X mixture of 
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phosphatase/protease inhibitors (#P2714, P0044, and P5726, Sigma). Homogenates were then 
incubated on a rotor at 4°C for 1 hr. Cell debris was removed by centrifugation at 10,000 x g for 
10 min at 4°C. Quantification of total protein in each aortic lysate sample was determined by a 
bicinchoninic acid assay with bovine serum albumin as a standard. For measures of aortic protein 
expression, 15 µg of protein with LSB were loaded on 4-12% gradient gels, separated by 
electrophoresis, and transferred onto a nitrocellulose membrane. The membrane was blocked in 
5 % non-fat dry milk in Tris-buffered saline with 0.1% Tween-20 (TBST) for at least 1 hr at room 
temperature. After blocking, the membrane was washed with TBST and incubated with primary 
antibody overnight at 4°C followed by washing with TBST. The membrane was incubated with 
appropriate secondary antibody. The immunoreactive bands were detected with ECL western 
blotting substrate (#32106, Thermo Sci), and quantified by densitometric scanning using ImageJ 
software. 
 
Citrate synthase activity assay 
Gastrocnemius muscles from SED and EX mice were dissected and flash frozen in liquid nitrogen. 
Frozen muscles were weighed, transferred to pre-chilled glass tissue grinding tubes (Kontes, 
Vineland, NJ), and homogenized 1:20 (wt:vol) in ice-cold lysis buffer (50mM TRIS-HCl, 1mM 
EDTA, 0.1% Triton X-100, pH 7.2) using a glass pestle attached to a motorized homogenizer 
(Caframo, Wiarton, ON). Homogenates were then incubated on a rotor at 4°C for 1 hr. The lysates 
were centrifuged at 10,000 x g for 10 min at 4°C to remove cell debris. Quantification of total 
protein in each aortic lysate sample was performed by a bicinchoninic acid assay with bovine 
serum albumin as a standard. Two micrograms of gastrocnemius homogenate were used. Citrate 
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synthase activity was determined using an assay kit according to the instructions (#701040, 
Cayman).   
 
Assessment of aortic endothelial function 
Following the tissue harvest, the thoracic aorta was dissected and placed in a dissection petri dish 
filled with cold physiological salt solution (PSS, mmol/L: 130 NaCl, 4.7 KCl, 1.18 KHPO4, 1.17 
MgSO4, 1.6 CaCl2, 14.9 NaHCO3, 5.5 dextrose, and 0.03 EDTA). After removing connective 
tissue, segments (2-3 mm in length) of aorta were mounted on pins in a myograph system (model 
610M, Danish Myo Technology, Aarhus, Denmark). Vessels were slowly warmed (37°C) and 
aerated (95% O2 and 5% CO2) in PSS for 20 min. Rings were set at 700 mg passive tension and 
equilibrated for 60 min with washing with pre-warmed and aerated PSS every 20 min. Prior to 
performing concentration response curves, vessels were subjected to osmotically balanced 60 mM 
potassium physiological salt solution (mmol/l: 14.7 NaCl, 100 KCl, 1.18 KHPO4, 1.17 MgSO4, 
1.6 CaCl2, 14.9 NaHCO3, 5.5 dextrose, and 0.03 EDTA). After washing, the vessels were 
contracted with 100 mmol/L KPSS until plateau, followed by washes. Phenylephrine (PE, 10-9 
mol/L to 10-4 mol/L) was added cumulatively to establish a concentration-response curve, in which 
PE EC80 was calculated for each individual ring. The vessels were contracted with their individual 
PE EC80 values and allowed to reach a stable plateau. Subsequently, acetylcholine (ACh) or 
sodium nitroprusside (SNP) was added cumulatively to the chamber to determine endothelium-
dependent (ACh) or endothelium-independent (SNP) relaxation. All chemicals used in the vascular 
reactivity study were purchased from Sigma (St. Louis, MO). The vascular reactivity to ACh or 
SNP was presented on a percent basis according to the following formula: Relaxation (%) = (TPE80 
– Td) / (TPE80) x 100, where TPE80 is the steady-state tension produced after addition of PE EC80, 
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and Td is the steady state tension following addition of vasoactive agent (ACh, SNP). Sensitivity 
(EC50) was defined as the concentration of the agent that produced 50% of its maximal response.  
A total of eight mice per group were utilized for these studies. 
 
Statistical analysis 
GraphPad Prism software was used for statistical analysis. The data were presented as mean ± 
standard error of the mean. Results were analyzed using the unpaired t-test for comparison of two 
groups. For vascular reactivity studies using ACh or SNP, concentration-response data was 
analyzed using two-way ANOVA (exercise and concentration) to compare the concentration-
response curves between the EX and SED groups. Bonferroni’s post hoc test was used to assess 
differences at individual points on the concentration-response curves if the results of the two-way 




Overall effects of voluntary wheel running on non-vascular endpoints 
The mice in the voluntary running wheel group (EX) ran on average 10 ± 0.75 km/day (Figure 5 - 
1A). During the first week of the exercise intervention, food intake was not different between the 
mice in the sedentary control (SED) and EX groups (Figure 5 - 1B). In the second week, consistent 
with the increased running distance, EX mice consumed 24% more food compared to SED mice. 
Interestingly, body weights were not different at the completion of voluntary wheel running (VR) 
compared to the beginning of VR in both SED and EX mice (Figure 5 - 1C). Despite no changes 
in total body mass, 12 weeks of VR resulted in a significantly higher heart to body mass ratio and 
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lower gonadal fat to body mass ratio in EX mice compared to those in SED mice (Table 5 - 1). 
The activity of citrate synthase as a marker for mitochondrial content was also measured to confirm 
an exercise training effect (33, 36). Consistent with the results in running distance, there was a 49% 
increase in the citrate synthase activity in gastrocnemius muscle of EX mice compared with SED 
controls (Figure 5 - 2). 
 
VR increases Akt / AMPK / eNOS signaling pathways in the aorta of EX mice 
Exercise has been shown to increase eNOS activity, in part, through shear stress (55). Akt and 
AMPK have been proposed to be critical mediators of shear stress-induced eNOS activation (5). 
The expression and phosphorylation status of Akt, AMPK, and eNOS were determined to test the 
hypothesis that VR induced changes in signaling pathways in the aorta. For these measurements, 
phosphorylation site-specific antibodies were used to probe immunoblots from the aortic 
homogenates from SED and EX mice. As shown in Figure 5 - 3, the ratio of p-AMPK (Thr-172) / 
t-AMPK was significantly higher (arbitrary units; 100 ± 9% vs. 137 ± 13%: SED vs. EX) in the 
aorta of EX than SED mice (Figure 5 - 3A). A significant increase in the p-Akt (Ser-473) / t-Akt 
ratio (arbitrary units; 100 ± 9% vs. 148 ± 17%: SED vs. EX) was also noted in the aorta of EX 
mice in comparison with SED mice (Figure 5 - 3B). It has been shown that phosphorylation of 
eNOS at Ser1177 is a major downstream target of Akt and AMPK in response to exercise and 
shear stress (55). Consistent with the previous finding, we observed a significantly higher p-eNOS 
(Ser-1177) to total eNOS ratio (arbitrary units; 100 ± 10% vs. 154 ± 12%: SED vs. EX) in the 
aorta of EX mice when compared to that of SED mice (Figure 5 - 3C). In addition, eNOS protein 
expression was significantly elevated (arbitrary units; 100 ± 2% vs. 120 ± 4%: SED vs. EX) in 
the aorta of EX in comparison with SED mice (Figure 5 - 3D). These results suggested that 12 
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weeks of VR intervention mediated an increase in expression and activity of eNOS and its 
upstream signaling kinases by which exercise/shear stress exert the beneficial effects on the 
endothelium. 
 
Nitric oxide and oxidative stress levels 
In previous studies increased levels of oxidative/nitrosative stress was observed in tissues of 
patients with Fabry disease and GLA-deficient mice (10, 39, 49). Thoracic aortae were used to 
determine the effects of VR on nitrotyrosine (NT) abundance, a cellular marker of peroxinitrite 
formation, therefore vascular oxidative/nitrosative stress (14). In this study, VR did not alter the 
level of NT in the aortic tissue (Figure 5 - 4A), suggesting the balance between NO and superoxide 
did not change significantly by VR. NO level in response to exercise was next determined in the 
aorta. Soluble guanylate cyclase is the major physiological receptor for NO and catalyzes the 
synthesis of intracellular cGMP level (3). Activated by cGMP is protein kinase G that 
preferentially phosphorylates vasodilator-stimulated phosphoprotein (VASP) at Ser-239 (22, 41). 
We observed no changes in p-VASP (Ser 239) to t-VASP ratio in response to 12 weeks of VR 
(Figure 5 - 4B). Because VASP is a common marker used for monitoring NO availability (41), 
this suggests no improvement in NO/cGMP signaling with VR. In addition, VR had no effect on 
the protein expressions of Mn-, CuZn-, and ec-SOD in the aortae of EX compared to SED mice 
(Figure 5 - 5A-C). Finally, we determined the effect of VR on NADPH oxidase, a prominent source 
of vascular-derived reactive oxygen species, in the aorta (23). Phox67 is one of the subunits of 
NADPH, and has been found to be reduced in aorta of mice following VR training (15). In the 
present study, VR did not alter phox67 subunit protein expression in EX mice compared to SED 





The vascular contraction mediated by 100 mmol/L KPSS was equivalent in aortae from SED and 
EX mice (1351.81 ± 117.09 mg vs. 1511.36 ± 105.54 mg, n=8/group, p>0.05). Phenylephrine (PE) 
caused a concentration-dependent contraction in isolated aortic rings from both SED and EX mice 
(Figure 5 - 6A). The PE-induced contractions were equivalent in aortae from SED and EX mice 
as demonstrated by similar log EC50 values (-6.58 ± 0.01 vs. -6.63 ± 0.02, p>0.05) as well as 
equivalent Emax values (140.83 ± 4.71% vs. 140.60 ± 10.01%, p>0.05). Based on the PE-induced 
contraction response, PE EC80 was calculated for each aortic ring. Receptor-mediated 
endothelium-dependent relaxation to acetylcholine (ACh) was examined in aortic rings from SED 
and EX mice. The vessels from SED and EX mice were dilated to ACh in a dose-dependent manner 
(Figure 5 - 6B). Both the maximal relaxation elicited by ACh (36.21 ± 7.88% vs. 44.0 ± 7.04%, 
p>0.05) and log EC50 values (-6.73 ± 0.14 vs. -6.78 ± 0.12, p>0.05) did not differ between the 
groups. Sodium nitroprusside (SNP) induced a concentration-dependent, endothelium-
independent relaxation in isolated aortae from SED and EX mice (Figure 5 - 6C). However, SNP-
mediated vasodilation was greater in the aortic rings from both SED and EX mice (67.89 ± 7.48% 
vs. 74.75 ± 6.05%) than the endothelium-dependent dilation to ACh (Figure 5 - 6B), suggesting 
the low magnitude of relaxation to ACh was not due to changes in the sensitivity of vascular 





Previous research regarding Fabry disease has focused on the pathophysiologic mechanisms using 
both patients and mouse models (4, 16, 38, 40, 43, 47). However, few studies have investigated 
the potential effects of exercise training on endothelial dysfunction in Fabry disease (45). In this 
study, we examined whether 12 weeks of VR intervention could improve endothelial dysfunction 
in the presence of eNOS uncoupling in a mouse model of Fabry disease. Our results indicate that 
in aged mice with Fabry disease, VR (a) induced exercise training adaptations, (b) increased 
Akt/AMPK/eNOS signaling pathways in the aorta, but (c) did not improve endothelial dysfunction 
and systemic markers of oxidative stress in the aorta and plasma.  
Our finding that VR induced training adaptations in tissues was supported by an increase in heart 
size and skeletal muscle citrate synthase activity. After 12 weeks of VR, a heart to total body mass 
ratio was higher in EX compared to SED mice. In addition, the magnitude of the increase in citrate 
synthase activity observed in EX compared to SED mice was comparable with a previous study 
examining the skeletal muscle of wild-type C57BL/6J mice following voluntary wheel exercise 
(20). 
EX mice had 54% and 20% higher levels of aortic p-eNOS at Ser1177 and protein expression of 
eNOS, respectively, compared to SED mice. One possible mechanism by which VR augmented 
eNOS activity as well as protein expression is through an activation of upstream kinases of eNOS 
by an increase in shear stress during exercise. Several lines of evidence have demonstrated that 
eNOS mRNA and protein expression are increased in endothelial cells exposed to shear stress (11, 
12), in isolated coronary arterioles subjected to elevated intraluminal flow (53, 54), and in the aorta 
from exercise trained mice (12, 24, 32, 34) and rats (2). In a previous study, shear stress increased 
eNOS activity, measured by NO production and phosphorylation of eNOS at S1177, via 
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PI(3)K/Akt-dependent pathway in HUVEC cells, which was prevented by wortmannin and in cells 
transfected with dominant-negative Akt mutant (13). Zhang et al. showed that arterial p-eNOS 
S617, which is activated by Akt alone, and p-eNOS S1177, which is activated by both Akt and 
AMPK, were increased in response to treadmill-running in mice (55). In the same study, 
intraperitoneal administration of wortmannin before treadmill running revealed either Akt or 
AMPK alone might be sufficient to activate p-eNOS S1177 during exercise. As such, we 
determined activation status of Akt and AMPK in the aorta in response to VR in this study. In 
keeping with the previous findings, we observed elevated levels of phospho -Akt (S473), -AMPK 
(T172), and -eNOS (S1177) in the aorta of EX in comparison with SED mice. 
Previous study in our lab has observed that endothelial dysfunction in the aorta was evident in 3-
5 month-old GLA deficient mice, characterized by decreased maximal vasodilation to ACh in the 
aorta (Emax: ~60%) (43). In the present study, the Emax to ACh in GLA deficient mice at 11-13 
months was approximately 40%. Another group reported 25% of Emax to ACh in the same mice at 
19 months (28). These results indicate a progressive decline in endothelial function in Fabry 
disease. Indeed, endothelial dysfunction in the mesenteric artery and accelerated oxidant-induced 
thrombosis in the setting of GLA deficiency in other studies were all shown to be age-dependent 
(16, 30). A previous study by Durrant el al. showed that carotid artery vasodilatation to ACh was 
improved in older mice of an aging model subjected to 10-14 weeks of voluntary running 
compared to their age-matched sedentary counterparts (15). On the other hand, some studies have 
reported that exercise did not improve endothelial function and/or arterial stiffness despite 
significant improvement in VO2peak or p-eNOS S1177 (31, 50). One possible reason that VR did 
not improve endothelial relaxation in the aged Fabry mice in the current study might be related to 
the rapid inactivation of NO by reactive oxygen species (ROS). In the presence of elevated ROS, 
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NO binds to superoxide to form peroxynitrite, a powerful oxidizing intermediate (21). NT has been 
used as a specific marker of the presence of reactive oxygen/nitrogen species (15, 29). In a previous 
study, an age-related increase in NT in the aorta of older mice of an aging model was attenuated 
by VR with a corresponding increase in SOD and decreased NADPH oxidase activity (15). 
However, in the current study, the levels of NT were unaltered by VR. Furthermore, the 
phospho/total VASP ratio and the expressions of SODs and p67phox, an important regulatory 
subunit of NADPH oxidase, did not differ significantly between EX and SED mice, indicating no 
changes in the balance between NO availability and oxidative/nitrosative stress. In previous studies 
NT levels of GLA deficient mice were significantly elevated even at 2 months of age compared to 
wild type mice, suggesting oxidative stress in this setting does not simply represent normal age-
related alterations (30, 49). Rather, the changes likely represent direct and/or indirect consequences 
resulting from Gb3 accumulation and related pro-inflammatory conditions, such as elevated ROS 
and eNOS uncoupling (47, 49). These results suggest that the expected shear stress-induced 
benefits on endothelial function may have been prevented by the presence of elevated ROS level 
in these aged Fabry mice.  
Another potential reason that the elevated eNOS activity did not translate to improvement in 
endothelial function in the aorta might be advanced morphological alterations of the smooth 
muscle cells and extracellular matrix preceding the VR intervention. For example, the aortae from 
GLA deficient mice displayed less sensitive endothelium-independent relaxation with an NO 
donor compared to wild type mice, suggesting alterations in vascular smooth muscle cells (SMC) 
(43). Heare et al. reported that aortic wall thickness of GLA-deficient mice was significantly 
increased with high Gb3 storage level in endothelium and vascular SMC compared with wild type 
mice (28). Progressive thickening of the intima-media layers of radial arteries was also observed 
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in patients with Fabry disease (6). One hypothesis is that accumulation of lyso-Gb3 
(globotriaosylsphingosine) in the SMC promotes SMC proliferation resulting in increased intima-
media thickness in the setting of Fabry disease (1). Gb3 accumulation in the endothelial cells has 
also been reported to increase ROS and cellular adhesion molecules (47). Often, these pathological 
conditions are associated with inflammation, hypertrophy, apoptosis, and replacement fibrosis in 
older patients with Fabry disease (48, 51). Thus, VR may not be able to reverse the age-related 
alterations that have accumulated before the initiation of the intervention in Fabry disease. Taken 
together, these data indicate that our exercise intervention does not reverse endothelial dysfunction 
and oxidative stress level in these aged GLA-deficient mice. 
Several limitations exist in our study. First, age-matched wild-type mice were not included for a 
direct comparison of the measurements with GLA-deficient mice. However, we and others have 
previously demonstrated endothelial dysfunction in younger and older mice with Fabry disease 
compared to age-matched wild-type mice (28, 30, 43). In addition, the primary goal of the present 
study was to gain initial insight into the effects of exercise on endothelial dysfunction and changes 
in signaling pathways in aged mice with Fabry disease. Finally, we assessed the levels of signaling 
kinases in aortic homogenates rather than in the aortic endothelial cells alone. However, a recent 
study, using phospho-protein-specific antibodies with immunohistochemistry analysis, 
demonstrated that exercise induced an activation of AMPK with concurrent elevation of p-eNOS 
S1177 in the endothelial cells to a greater extent than those in the smooth muscle cells in the aorta 
of mice (9). Although our study bears some limitations, this is the first study to evaluate the 
influence of voluntary running on endothelial function in a mouse model of Fabry disease. 
In conclusion, VR significantly improved Akt/AMPK/eNOS signaling pathways without 
improvement of the severe endothelial dysfunction evident in the aorta of aged mice with Fabry 
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disease. This finding has clinical relevance to Fabry disease treatment by supporting the notion 
that early intervention may be necessary for clinical improvements. Emerging clinical data 
evaluating the effectiveness of long-term enzyme replacement therapy indicated that this therapy 
does not prevent the occurrence of new cardiovascular complications in Fabry patients with more 
advanced disease (44). Furthermore, another recent study demonstrated that Fabry patients 
without myocardial fibrosis, compared to those with myocardial fibrosis, showed better 
outcomes regarding left ventricular mass, improved myocardial function, and a higher exercise 
capacity during 3 years of enzyme replacement therapy (52). Similarly, the findings of this study 
raise a primary question of whether exercise might suppress the progression of endothelial 
dysfunction in this setting if started earlier in this disease process. Future studies examining the 
effects of exercise in younger age or as an adjuvant treatment with enzyme replacement therapy 
will further our understanding of the effects of exercise as a potential strategy for preventive and 
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Figure 5 - 1. Daily running distance and changes in food intake and body weight in SED 
and EX mice during 12-week voluntary wheel intervention 
Graphs show A. the average daily running distance (km/day), B. food intake (g/day); *p<0.001 
compared to SED mice, and C. changes in body weight expressed as percent of that at the 
beginning of the 12-week voluntary wheel intervention (n=19/group). *p<0.05 compared to 




Table 5-1. Summary of parameters of SED and EX mice  
      SED EX 
Final body weight (g) 35.1 ± 0.6 34.0 ± 0.6 
Food intake (g/day) 5.4 ± 0.1 6.9 ± 0.2* 
Heart (mg)  198.4 ± 5.6 225.0 ± 6.2* 
Heart:BW (g/g x 100) 0.57 ± 0.01 0.66 ± 0.01* 
Gonadal fat (mg)  533.7 ± 46.1 277.9 ± 18.7* 
GF:BW (g/g x 100)   1.50 ± 0.12 0.82 ± 0.06* 
 

















Figure 5 - 2. Increased citrate synthase activity in gastrocnemius muscle from EX mice 
Gastrocnemius muscle was homogenized as described in the method section. Citrate synthase 
activity in muscle homogenate was determined by measuring the production of SH-CoA from 
the condensation of dicarboxylate oxaloacetate and acetyl CoA by citrate synthase (n=8/group). 








Figure 5 - 3. Increased p-AMPK, p-Akt, and p-eNOS in the aorta of EX mice 
An equal amount of aortic homogenates was separated by SDS-PAGE. Representative blots 
were shown above each summary graph. A. Phospho-AMPKα (Thr172) was normalized to total 
AMPKα expression and expressed relative to SED mean (n=7/group). *p<0.05. B. Phospho-Akt 
(Ser473) was normalized to total Akt expression and expressed relative to SED mean 
(n=7/group). *p<0.05. C. Phospho-eNOS (Ser1177) was normalized to total eNOS expression 
and expressed relative to SED mean (n=7/group). *p<0.01. D. Total eNOS protein expression 







Figure 5 - 4. Levels of ROS/RNS and NO bioavailability in the aortic tissue 
An equal amount of aortic homogenates was separated by SDS-PAGE. Representative blots 
were shown above each summary graph. A. Nitrotyrosine abundance was normalized to 
GAPDH and expressed relative to SED mean (n=7/group). B. Phospho-VASP (Ser239) level 







Figure 5 - 5. Levels of SOD and phox67 subunit of NADPH oxidase in the aorta of SED 
and EX mice 
An equal amount of aortic homogenates was separated by SDS-PAGE. Representative blots 
were shown above each summary graph. A. SOD1 was normalized to GAPDH and expressed 
relative to SED mean (n=7/group). B. SOD2 was normalized to GAPDH and expressed relative 
to SED mean (n=7/group). C. SOD3 was normalized to GAPDH and expressed relative to SED 
mean (n=7/group). D. The level of phox67, a subunit of NADPH oxidase, was normalized to 





Figure 5 - 6. Endothelium-dependent and -independent aortic vascular relaxation in SED 
and EX mice with Fabry disease 
A. Phenylephrine (PE)-mediated vascular contraction in aortic rings from SED and EX mice 
was expressed as percentage maximum response to KPSS (n=8/group). B. Acetylcholine (ACh)-
mediated endothelium-dependent relaxation in the aortic rings from SED and EX mice was 
expressed as a percentage relaxation of the pre-contraction elicited by PE EC80 (n=8/group). C. 
Sodium nitroprusside (SNP)-mediated endothelium-independent relaxation in the aortic rings 
from SED and EX mice was expressed as a percentage relaxation of the pre-contraction elicited 
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It is very clear that cardiovascular disease and stroke contribute to the immense health and 
economic burdens in the United States and globally (11). Although the rates of cardiovascular 
disease have declined over decades, heart disease, stroke, and related vascular deaths still remain 
as the leading causes of morbidity and mortality in the United States (10). Endothelial dysfunction 
has been associated with the primary risk factors for cardiovascular disease, including smoking, 
physical inactivity, obesity, diabetes, hypertension, and dyslipidemia. Endothelial dysfunction is 
characterized by reduced bioavailability of vasodilators, in particular nitric oxide (NO), and 
considered as a key early step in atherosclerosis and a contributor to arterial thrombosis. Fabry 
disease is caused by α-galactosidase A (GLA) deficiency, which has pleiotropic effects on multiple 
organ tissues, resulting in renal disease, cardiomyopathy, and vasculopathy associated with 
accumulation of globo-series glycosphingolipids including globotriaosylceramide (Gb3). 
However, Gb3 has been implicated in other pathological conditions as well. For example, 
hemolytic-uremic syndrome (HUS), characterized by the classic presentation of acute renal injury, 
microangiopathic hemolytic anemia, and thrombocytopenia, is the leading cause of acute renal 
failure in children and associated with enteric infection by Shiga toxin-producing organisms, 
predominantly Escherichia coli (13). Although most patients of hemolytic-uremic syndrome 
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normally recover from kidney damage completely, approximately 5% of patients with hemolytic-
uremic syndrome die by damage to the brain (18). A previous study has shown that elevated levels 
of inflammatory cytokines markedly increased brain endothelial cell surface Gb3 expression, a 
receptor for Shiga toxin, and brain endothelial cell damage (19). Furthermore, a recent study has 
revealed that elevated urinary Gb3 is positively associated with near-term mortality in heart disease 
patients who do not have Fabry disease (15), suggesting abnormalities in glycosphingolipid 
metabolism are associated with cardiovascular diseases beyond this rare lysosomal storage 
disorder. Therefore, Fabry disease provides a unique model to explore the link between Gb3 
accumulation and endothelial dysfunction, findings of which may be applied to a broader 
population with cardiovascular disease. Using this Fabry model, my dissertation projects were 
designed to further characterize the causes and consequences of endothelial dysfunction and 
inflammation in Fabry disease. Furthermore, the effects of an exercise intervention on endothelial 
function were examined in the setting of eNOS uncoupling as present in mice with Fabry disease. 
Together, the three of my dissertation projects discussed herein have enhanced our understanding 
of the effects of: 1) GLA deficiency on microvascular endothelial dysfunction; 2) the disruption 
of GLA on the secretion of endothelial-derived VWF; and 3) exercise on aortic endothelial 
function and signaling alterations related to eNOS activity in the setting of GLA deficiency. 
Important findings of my dissertation studies include that: A) the GLA deficiency resulted in an 
early endothelial dysfunction in the mesenteric artery associated with Gb3 accumulation and eNOS 
uncoupling (STUDY 1); B) the genetic disruption of GLA in endothelial cells directly promoted 
decreased eNOS activity and elevated VWF secretion (STUDY 2); C) improving NO level or 
scavenging reactive oxygen species (ROS) inhibited VWF release in the setting of GLA deficiency 
(STUDY 2); and D) 12 weeks of voluntary wheel exercise improved signaling cascades of selected 
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kinases that are known to activate eNOS in the aorta without alterations of endothelial function in 
older mice with Fabry disease (STUDY 3). In this overall summary of my dissertation, I will 
attempt to expand on the findings of my projects and provide an integrative discussion of the 
collective implications that can be derived from my dissertation studies.  
The key underlying component of all three of my dissertation studies was the examination of the 
hypothesis that dysregulation of eNOS is an important underlying basis for the vasculopathy in 
Fabry disease. The basis for this hypothesis was largely generated from previous studies of Gla-
deficient mice and in vitro endothelial models of Fabry disease. Briefly, Gla deficient mice 
demonstrated a marked increase in atherosclerotic plaque lesion on an apoE1-deficient background 
compared to wild type mice (1). In another model, when arterial injury was induced in the carotid 
artery by the release of photochemical-mediated reactive oxygen species, Gla knockout mice 
exhibited a higher propensity for thrombosis than wild type mice (5). In a third model, aortic rings 
from Gla-deficient mice demonstrated impaired relaxation to acetylcholine (12). Finally, 
disruption of GLA in a human endothelial cell line, EA.hy926, showed decreased eNOS activity 
and robust elevation in 3-nitrotyrosine, a marker for eNOS uncoupling (17). Both STUDY 1 and 
STUDY 2 of my dissertation provide further support for the previous hypothesis. In STUDY 1, I 
reported that Gla-deficiency promoted an early profound reduction (~70%) in acetylcholine-
mediated, endothelium-dependent relaxation in the mesenteric artery of Gla-null mice at 2 months 
of age compared to wild type mice. In an older age (8 months), the endothelium-dependent 
relaxation in the mesenteric artery of Gla knockout mice was completely absent. These conditions 
were associated with increased eNOS uncoupling at the younger age and changes in eNOS-
regulatory phosphorylation sites at the older age. In STUDY 2, both short-term and permanent 
deletion of GLA from cultured endothelial cells promoted a decrease in eNOS activity (~60%) 
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similar to a previous study (17). Subsequently, a robust increase in VWF release from endothelial 
cells was observed when GLA was disrupted. Using VWF as a biomarker for endothelial 
dysfunction in these cells, I have found that pharmacological treatments that increase eNOS 
activity and NO level or decrease reactive oxygen and nitrogen species completely normalized the 
elevated VWF secretion in GLA deficient cells. However, recombinant GLA, the current standard 
of care for Fabry disease, did not improve endothelial dysfunction. This finding is important 
because strokes continue to occur in advanced Fabry disease patients while receiving recombinant 
GLA replacement therapy. The findings of STUDY 2 support the previous hypothesis of eNOS 
dysregulation as an important basis of the underlying vasculopathy in GLA deficiency and 
advocate for new possible strategies to improve endothelial dysfunction in Fabry disease.  
Although my dissertation studies generally reaffirmed the major concepts of the current hypothesis, 
the widely accepted dogma that exercise can reverse an existing endothelial dysfunction in 
pathological conditions, was not supported in STUDY 3. For example, several studies examining 
patients with CAD have demonstrated that aerobic exercise training improves endothelium-
dependent coronary artery dilatation as well as blood flow in CAD patients (7, 8). This 
improvement in endothelial function was associated with elevated eNOS expression and 
phosphorylation at serine1177 (S1177), a major eNOS activating phosphorylation site. The 
beneficial effects of exercise on endothelial dysfunction through activation of eNOS were also 
observed in the setting of sedentary aging (4, 20). In these studies, 3 months of aerobic exercise 
intervention restored the impaired arterial compliance and endothelium-dependent vasodilatation 
in sedentary middle-aged and older men to the level of those in healthy young men. It is important 
to note that beginning an exercise program in healthy men at any stage of life yielded significant 
cardiovascular health benefits (4, 20). However, in STUDY 3, I have found that 12 weeks of 
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exercise intervention did not improve endothelial dysfunction in the aorta of GLA deficient mice 
despite the activation of AMPK/Akt/eNOS signaling pathways. A previous study demonstrated 
that activating eNOS through S1177 phosphorylation under a complete BH4 depletion, a condition 
known to induce eNOS uncoupling, leads to increased superoxide production from the enzyme in 
vitro (3). However, in STUDY 3, the activation of eNOS in the setting of severe eNOS uncoupling 
(i.e. Fabry diease) in vivo was found not to be detrimental.  
Several important findings from STUDY 3 gave rise to questions as to 1) why was the endothelial 
function not improved despite the eNOS activation?, and 2) does this portend that endothelial 
dysfunction is not reversible in this setting? One possible explanation would be the presence of 
advanced morphological alterations of the smooth muscle cells and/or extracellular matrix that 
may have preceded the exercise intervention. This notion is supported by several previous 
observations. For example, aortic wall thickness of GLA-deficient mice has been reported to be 
significantly increased compared with wild-type mice (9). In addition, progressive thickening of 
the intima-media layer of radial arteries was also observed in patients with Fabry disease (2). These 
previous observations together with the results of STUDY 3 raise another question of whether 
exercise can delay/prevent the development of endothelial dysfunction and eNOS uncoupling if 
started earlier in this disease process. This hypothesis that timing of intervention would be 
important is substantiated by previous observations. Weidemann et al. studied the effects of 
enzyme replacement therapy (ERT) over a period of 3 years on disease progression and clinical 
outcomes (left ventricular mass, myocardial function, and exercise capacity) in three groups of 
Fabry patients with no, mild, and severe fibrosis (21). ERT resulted in a significant improvement 
in all of these clinical outcomes only in the patients without left ventricular fibrosis. In comparison, 
the patients with mild or severe fibrosis revealed only a minor reduction in left ventricular mass 
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and no improvement in myocardial function or exercise capacity in response to ERT. This 
observation indicates that once irreversible structural changes such as fibrosis are present, ERT 
has only minor effects in Fabry patients. It follows, therefore, that an early intervention with ERT 
could provide greater protection regarding important cardiovascular complications, including 
stroke. Gb3 accumulation has been hypothesized to be the main mechanism that causes the 
vasculopathy in Fabry disease. This hypothesis seems reasonable because the metabolites that 
accumulate as a result of GLA deficiency, such as Gb3 and lyso-Gb3, have been demonstrated to 
directly or indirectly promote decreased NO level and elevated ROS production (14, 16). However, 
despite the efficacy of ERT on clearing stored globo-series glycosphingolipids from endothelium, 
it has become clear that enzyme replacement has limited impact on the prevention of important 
cardiovascular complications in Fabry disease. This suggests that even though Gb3 could be the 
causal basis for the initial ROS production and decreased NO level, the more complex alterations 
in vascular function occur once the disease is far advanced. Under chronically elevated ROS, 
bioavailability of NO is decreased by a reaction with superoxide, leading to the formation of 
peroxynitrite (6). Peroxynitrite is a potent oxidant, capable of oxidizing BH4, an important cofactor 
for eNOS (6). With reduced BH4 level, eNOS becomes uncoupled, producing more superoxide 
and less NO, which promotes further uncoupling of the enzyme. Thus, the endothelial cells enter 
a vicious cycle (Figure 6) where eNOS dysregulation is exacerbated. Therefore, in the advanced 
stage of Fabry disease, it is possible that simply removing Gb3 may not be sufficient to “recouple” 
eNOS in the presence of elevated ROS. The findings of STUDY 2 support this hypothesis. Using 
VWF as a marker for endothelial dysfunction, I have shown that GLA deficiency can directly 
promote eNOS dysregulation and VWF release in cell culture. Furthermore, providing human 
recombinant GLA back to the deficient cells resulted in only a partial decrease in the VWF 
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secretion, suggesting endothelial cells remained dysfunctional. In contrast, the pharmacological 
agents that are known to increase exogenous NO availability, correct eNOS uncoupling, or to 
decrease ROS level were demonstrated to inhibit VWF exocytosis in cell culture. Therefore, the 
clinical observation of continued cardiovascular disease complications during ERT, including 
cerebrovascular events, may be due to an incomplete restoration of the balance between NO and 
ROS, and endothelial inflammation. In Study 3, the exercise intervention (non-pharmacological 
approach) was observed to improve signaling cascades of eNOS activation. Considering these 
observations together, it is plausible to hypothesize that adjuvant therapies improving NO levels 
by (non)pharmacological approaches with ERT in an earlier stage of the disease process may have 
beneficial effects in Fabry disease.  
Currently, it is challenging to demonstrate the efficacy of ERT or alternate treatment strategies 
specifically for Fabry disease due to the following reasons: 1) a heterogeneous phenotype of 
patients, 2) a difficulty to recruit enough number of patients with this rare disease, and 3) the 
necessity of long-term follow-up studies that use stroke, myocardial infarction, and death as 
endpoint measures due to the lack of biomarkers. In STUDY 1, I have found an early endothelial 
dysfunction in the mesenteric artery, which was exacerbated in an age-dependent manner. Plasma 
VWF, but not sVCAM-1, of GLA-deficient mice was associated with the presence of endothelial 
dysfunction and eNOS uncoupling (STUDY 1 and 2). These results collectively suggest that VWF 
may reveal the presence and/or degree of endothelial dysfunction in Fabry disease. Future studies 
should evaluate whether VWF levels may be useful to determine the risk of stroke and myocardial 




In summary, my dissertation projects support our current understanding that endothelial 
dysfunction is an important mechanism contributing to the accelerated cardiovascular disease 
complications in Fabry disease. Specifically, my dissertation projects provide the first evidence 
that: A) GLA-deficiency causes profound endothelial dysfunction in the mesenteric artery in an 
early stage of the disease, B) the disruption of GLA in endothelial cells directly promotes 
endothelial inflammation and VWF secretion, which is inhibited by restoration of NO level, and 
C) exercise increases signaling cascades that are shown to activate eNOS without significant 
improvement in aortic endothelial relaxation in GLA deficient mice. My dissertation STUDIES 1-
3 collectively reaffirm the notion that the endothelium, as a primary interface between blood and 
body tissues, is an active organ whose normal function is crucial for maintaining vascular health. 
The results of my dissertation studies lay the foundation for future experiments to further 
understand the mechanisms of endothelial dysfunction and inflammation in Fabry disease, and 





Figure 6 - 1. GLA deficiency promotes eNOS uncoupling 
The loss of activity of the lysosomal GLA results in a toxic accumulation of globo-series 
glycosphingolipids in vascular endothelial cells. The Gb3 accumulation induces the formation 
of reactive oxygen species and oxidative stress. eNOS-derived NO binds to superoxide to form 
peroxynitrite, which reduces an important cofactor of eNOS, BH4, to BH2. In the absence of 
BH4, eNOS generates less NO and more superoxide and produces peroxynitrite, which promotes 
further uncoupling of eNOS. In this vicious cycle, replacement of GLA or removing Gb3 may 
not be sufficient to “recouple” eNOS. Abbreviations: GLA: α-galactosidase A; ROS: reactive 
oxygen species; ONOO-: peroxynitrite; BH4: tetrahydrobiopterin; BH2: dihydrobiopterin; eNOS: 
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Appendix I: Study 2 
 














Figure A - I 4 - 1. Elevated sICAM-1 level in WT and Gla deficient mice 
The blood was drawn via the retro-orbital plexus from male wild type (WT) and Gla deficient 
mice at the indicated ages. Levels of soluble intercellular adhesion molecule 1 (sICAM-1) were 
measured by ELISA (n=6/group and n=2-3/group at 2 and 12 months, respectively). *p < 0.02 















Figure A - I 4 - 2. Correlation between VWF and the number of cells 
EA.hy926 cells were grown in 75 cm2 flasks and trypsinized. Cell number was counted by 
hemocytometer. The indicated number of cells were lysed with lysis buffer, and VWF levels in 














Figure A - I 4 - 3. Histamine-evoked VWF release from EA.hy926 cells with different days 
of confluency 
EA.hy926 cells were plated at 6 x 106 density in a 100 cm2 petri dish. The cells were grown for 
the indicated days above after cell confluency was attained. The cells were washed twice with 
0% FBS DMEM media and incubated in vehicle (DMEM) or histamine (100 µM) for 90 
minutes. The concentration of VWF released into media was determined by ELISA using a 







Figure A - I 4 - 4. Histamine-evoked VWF release in CRISPR cells 
CR-WT and CR-GLA cells were plated at 2 x 105 density in a 24-well plate. The cells were 
grown for 10 days after cell confluency was attained. The cells were washed twice with 0% FBS 
DMEM media and incubated in vehicle (DMEM) or histamine for 60 minutes. A. The 
concentration of VWF released into media was determined by ELISA using a dilution series of 
pooled normal plasma with known VWF antigen levels as standards (n=3/group). B. The VWF 
levels were expressed as fold changes with respect to CR-WT vehicle. C. The VWF levels were 












Figure A - I 4 - 5. The effect of DDAVP on VWF secretion in WT and Gla deficient mice 
The blood was drawn via the retro-orbital plexus from female wild type (WT) and Gla deficient 
mice at 10 months of age before an intravenous injection of desmopressin (DDAVP) at 3 µg/kg 
body weight. The blood was drawn again, 2 and 24 hours post DDAVP injection. Circulating 
plasma VWF levels were measured by ELISA (n=6-8/group). A dilution series of pooled 
platelet-poor plasma (PPP) from C56BL/6 mice (n=10) was used as a reference (100%). *p < 











Appendix II: Study 3 
 














Figure A - II 5 - 1. VWF levels in EX and SED mice at the completion of 12 weeks of 
voluntary wheel exercise training 
The blood was drawn from mice via the left ventricle using a 3 mL syringe and a 21 gauge 
needle preloaded with sodium citrate (1:9, v/v to blood) (n=19/group). Blood was centrifuged 
at 2,000 x g for 10 min at room temperature to obtain platelet-poor plasma. VWF antigen levels 
in the plasma was determined by ELISA. A dilution series of pooled platelet-poor plasma (PPP) 
from C56BL/6 mice (n=10) was used as a reference (100%). 
 
 
